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Acetaminophen is the most prevalent cause of acute liver failure (ALF) and drug-induced 
liver injury (DILI) in western countries. Extensive studies have revealed important 
intracellular events during the pathogenesis after APAP in vivo and in vitro. However, no 
detailed mechanistic research has been conducted in freshly isolated primary human 
hepatocytes (PHH), which are the gold standard to test drug-induced toxicity. To that end, 
the detailed injury time course, dose-response curves and signaling events were 
characterized. The overall time course and sequence of events mirror the clinical situation 
in APAP overdose patients, but occur significantly more slowly than in APAP-treated 
rodents, emphasizing cautious data extrapolation across experimental models. In addition, 
c-Jun N-terminal kinase (JNK) inhibitor moderately attenuated cell death after APAP, 
suggesting a detrimental role of JNK in injury progression.  
Although APAP-induced hepatotoxicity is reproducible in the murine model, it is not the 
case for AMAP, a regioisomer of APAP. AMAP was considered for long to be non-
hepatotoxic in mice, primary mouse hepatocytes (PMH), hamsters and hepatoma cell 
lines. The lack of toxicity was largely due to the significantly less mitochondrial protein 
adduct formation after AMAP compared with APAP. In PHH, significant cell death was 
observed after AMAP, accompanied by a loss of mitochondrial membrane potential and 
the absence of JNK activation or P-JNK translocation to mitochondria. Further 
investigation indicated that AMAP toxicity was readily explained by mitochondria 
protein adducts formation in primary human but not mouse hepatocytes, highlighting the 
critical role of mitochondrial protein arylation in determining APAP or AMAP 
hepatotoxicity. Additional studies were performed to investigate the toxicity of ATP in 
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vitro. ATP released from necrotic hepatocytes is considered a damage-associated 
molecular pattern (DAMP) molecule which could elicit innate immune responses, and 
therefore contributes to cell death. A recently published paper also suggested a direct 
toxicity of ATP. However, experiments in four different hepatocyte types including 
PHHs demonstrated an absence of toxicity directly by ATP. The fourth study focuses on 
characterization of APAP metabolites and adducts formation in APAP overdose patients, 
suggesting the importance of profiling both metabolites and protein adduct formation in 
the clinical diagnosis of APAP overdose. 
Given the importance of c-Jun N-terminal kinase (JNK) in APAP-induced liver injury, 
two pharmacological inhibitors of apoptosis signal-regulating kinase 1 (ASK1), an 
upstream kinase of JNK, were tested in mice. The ASK1 inhibitor attenuated liver injury 
both as a pre-treatment and as a 1.5h post-treatment by blocking JNK activation and P-
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1.1 Background of APAP 
 
Acetaminophen (APAP, N-Acetyl-Para-Aminophenol) is a worldwide popular analgesic 
and antipyretic. It is the top-selling generic drug, with around 120 million prescriptions, 
20 billion doses and 6 billion in sales each year (Lee, 2004; IMS, 2008; IMS, 2014). 
However, APAP is also the leading cause of either acute liver failure (ALF) or drug-
induced liver injury (DILI) in industrialized nations, such as the US and UK (Lee, 2012).  
APAP is different from most drugs on the market in many ways. First, there are no 
widely accepted scientific explanations for its pharmacological effects, while most of the 
drugs nowadays have very specific targets and mechanisms of actions to support their 
approval. Proposed mechanisms for APAP include increasing pain thresholds, 
modulating the endogenous cannabinoid system, and inhibiting cyclooxygenases. 
However, none of them have received widespread recognition (Ferreira et al., 1997; 
Botting 2000; Bertolini et al., 2006; Hinz et al., 2008). Second, current drugs are strictly 
regulated in terms of toxic responses. For the liver, drugs with 1/10000 incidence of liver 
dysfunction could face the risks of disapproval, market withdrawal or black box warning 
according to FDA guidance. In this regard, APAP would probably not be approved as a 
drug. 
The third difference between APAP and current drugs on the market is the discovery 
process. In contrast to current methodical drug development as practiced today, the 
discovery and application of APAP started with serendipity. As the last survivor of the 
aniline-derived analgesics, the popularity of APAP was preceded by the ups and downs 




simply due to a mistake by the local pharmacy as they accidentally replaced naphthalene 
with acetanilide, which lead to alleviated fever symptoms in patients. Commercialization 
of acetanilide followed immediately, accompanied by the discovery of side effects 
including methemoglobinemia which resulted in bluish skin (Prescott, 1996). The adverse 
effects of acetanilide sparked a search for safer alternatives, leading to the discovery of 
phenacetin. Phenacetin was widely used in the 1950s to reduce work-related headache 
and exhaustion, especially for factory workers. In the same group of people, nephropathy 
was observed and its relation to phenacetin intake was later pointed out (Dubach et al., 
1991). These undesirable effects of phenacetin and reports of Reye’s syndrome after 
aspirin paved the way for the popularity of APAP. However, APAP toxicity was later 
realized.  
Currently, APAP is the major cause of acute liver failure in western countries. Featuring 
coagulopathy and encephalopathy, acute liver failure is the result of hepatocyte 
dysfunctions. Without liver transplantation, the mortality of ALF exceeds 90% due to 
multi-organ failure, infection, cerebral edema and hemorrhage (Bernal et al., 2010). In 
the 1990s, although APAP was the most prevalent cause for ALF, the incidence was 
around 20~28% (Schiodt et al., 1999; Shakil et al., 2000). The number increased 
considerably to 39% between1998-2001, and even more to 51% in 2004 and 46% in 2012 
(Lee, 2004; Bernal et al., 2010; Lee, 2012). Several interesting facts about APAP deserve 
attention. First, mortality rates are higher in accidental APAP overdose patients than the 
suicidal patients using APAP, as the former are soon discovered and treated with NAC 
while the latter usually ingest APAP over days without knowing the harm (Schiodt et al., 




judgement and delays the hospitalization of patients, while on the other hand causes drug-
drug interactions which enhance inflammation and exacerbate liver injury (Thummel et 



















1.2 Intracellular mechanisms of liver injury after APAP 
 
1.2.1 APAP metabolism 
Acetaminophen is safe at therapeutic doses, whereas an overdose could trigger 
hepatotoxicity, liver dysfunction and even liver failure. After being ingested and 
absorbed, APAP reaches the liver through the portal vein. At therapeutic doses, around 
50% of APAP is conjugated with glucuronide and 30% is conjugated with sulfate. These 
reactions are catalyzed by UDP-glucuronosyltransferase (UGT) and sulfotransferase 
(SULT), especially UGT1A and SULT1 (de Morais et al., 1992; Court et al., 2001; 
Lindsay et al., 2008; Navarro et al., 2011). The resultant conjugates are removed from the 
hepatocytes into either bile or plasma through canalicular and basolateral transporters 
including multidrug resistant protein-2 (mrp2) and 3 (mrp3) as well as breast cancer 
resistant protein 1 (Bcrp 1). Studies using the plasma samples of APAP overdose patients 
indicated that, as the sulfation pathway was easily saturated, the distribution of APAP 
conjugation could be skewed to glucuronidation as much as 90% (Clements et al., 1984; 
Xie et al., 2015a). With the purpose of increasing water solubility of APAP metabolites 
and preparing them for excretion, these phase II conjugating reactions contribute 
significantly to the detoxification of APAP. Indeed, Gunn rats with impaired 
glucuronidation were more susceptible to APAP compared with other rat strains (de 
Morais and Wells 1989). In humans, polymorphisms of UGT1A allowed higher 
glucuronidation activities, and resultantly lower incidence of liver failure after toxic 
doses of APAP (Court et al., 2013). Therefore, deficiency in conjugating pathways 




In addition to the two phase II conjugation pathways, phase I metabolisms mediated by 
Cytochrome P450 enzymes account for the conversion of the remaining 5-10% APAP to 
the toxic metabolite N-acetyl- p- benzoquinone imine (NAPQI) (Dahlin et al., 1984). 
Note that, phase I and phase II metabolisms are not sequential but happen simultaneously, 
as subtoxic doses of APAP also elicit APAP protein adduct formation where phase II 
metabolisms are clearly not overwhelmed. Therefore, the saturation of phase II pathways 
is not a prerequisite for NAPQI formation (McGill et al., 2013).  
Among all CYP450s, CYP2E1 is the most important one for APAP bioactivation while 
CYP3A4, CYP1A2 and CYP2D6 are also involved. Evidence supporting the critical role 
of CYP2E1 comes from the observation that APAP-induced liver injury was exacerbated 
by isoniazid and alcohol which are inducers of CYP2E1 (Sato and Lieber, 1981; Zand et 
al., 1993; Thummel et al., 2000). Besides, genetic deletion of cyp2e1 desensitized mice to 
APAP hepatotoxicity, while transgenic expression of human cyp2e1 in cyp2e1-null mice 
restored the metabolic activities and hepatotoxicity after APAP (Lee et al., 1996; Cheung 
et al., 2005). A spectrum of chemicals, natural products and drugs can block CYP450 
activities and effectively prevent APAP toxicity. However, in studies testing the 
therapeutic interventions of APAP hepatotoxicity, suppression of APAP metabolism can 
lead to misinterpretations of the protective mechanisms by theses interventions. As 
inhibiting the upstream metabolic activation automatically shuts down the downstream 
events after APAP, further tests on the roles of downstream events are precluded and any 
related conclusions are unsupported (Jaeschke et al., 2011; Jaeschke et al., 2013). Cases 
in point are, an important and common solvent dimethyl sulfoxide (DMSO), ethanol, 




alcohol and a series of natural products (Jaeschke et al., 2006; Jaeschke et al., 2011; Du et 
al., 2013; Jaeschke et al., 2013; Xie et al., 2013). In those scenarios, inhibition of 
CYP450 enzyme activities invalidated any claims on alternative protective mechanisms 
like inhibiting sterile inflammation or enhancing antioxidant defense. To circumvent this 
issue, evaluations of metabolic activities and protein adduct formation at the initial phase 
after APAP are recommended, and a >1.5h posttreatment regime to avoid any 
interference on APAP metabolism is also helpful to confirm the protective mechanisms. 
1.2.2 Protein adducts 
As the principle toxic metabolite of APAP, NAPQI is an electrophile scavenged by 
conjugation with glutathione (GSH). This reaction could happen spontaneously or is 
catalyzed by glutathione-S-transferase (GST). Once GSH is depleted, the excessive 
NAPQI reacts with alternative targets, especially the sulfhydryl groups of cysteine 
residues on cellular proteins to form protein adducts (Streeter et al., 1984; Hoffmann et 
al., 1985). That being said, GSH depletion is not a prerequisite of protein adducts 
formation, as APAP-adducts are detectable after nontoxic dose of APAP when GSH is 
not exhausted (McGill et al., 2013).  
Arylation of cellular proteins represents a hallmark of APAP toxicity. However, follow-
up studies revealed that total protein adducts formation was necessary but not sufficient 
for liver injury. First, it is mitochondrial protein binding rather than total protein biding 
which correlates with injury. In mice, comparison of APAP with N-acetyl-meta-
aminophenol (AMAP), a nontoxic regioisomer of APAP, indicated that the disparity of 




even though the total protein binding were similar (Tirmenstein and Nelson 1989; Myers 
et al., 1995). This suggests that total protein binding does not necessarily lead to toxicity. 
Consistently, mitochondrial protein binding was significantly lower in rats which are 
resistant to APAP compared with mice (McGill et al., 2012b). Besides, in primary human 
hepatocyte where AMAP is toxic, mitochondria adduct level was significantly higher 
than in primary mouse hepatocytes which were resistant to AMAP (Xie et al., 2015b). 
Given these studies, it is generally believed that mitochondrial protein adduct levels 
rather than total protein adduct levels mirror APAP toxicity (Cohen et al., 1997; Qiu et al., 
2001; McGill et al., 2012b; Xie et al., 2015b).  Second, liver protein adducts were 
detectable at subtoxic doses like 75mg/kg, and therefore liver injury is not mandatory in 
the presence of total protein binding (Heard et al., 2011; McGill et al., 2013). Third, 
subsequent amplification processes involving apoptosis-signaling kinase (ASK1), c-jun 
N-terminal kinase (JNK), mixed-lineage kinase 3(MLK3), glycogen synthase kinase 3-β, 
receptor-interacting protein 1&3 (RIP1&3) are necessary for the execution of ultimate 
hepatocyte necrosis and liver injury, and these players will be further discussed below. 
Therefore, total protein binding is only an initiating event and does not necessarily lead to 
liver injury, while further amplification processes are necessary for ultimate cell death. 
As APAP-adducts could be detected in the serum of patients and also possess a longer 
half-life compared with APAP (Pumford et al., 1989; Muldrew et al., 2002), serum 
adduct measurement emerged as a diagnostic tool for APAP overdose in patients 
(Pumford et al., 1989; Muldrew et al., 2002; Davern et al., 2006; James et al., 2008). 
Although it holds promise for diagnosis, a translational study in serum of APAP overdose 




which could affect clinical diagnosis and timely treatment (Muldrew et al., 2002). To that 
end, a threshold of >1.1 nmol/ml APAP-cys together with ALT> 1000U/L was suggested 
as relevant for toxicity. In addition, evaluation of APAP metabolites could also assist in 
the diagnosis of APAP overdose (James et al., 2009; Heard et al., 2011; Xie et al., 2015a). 
1.2.3 Mitochondria 
The importance of mitochondria in APAP-induced hepatotoxicity was first revealed by a 
series of comparison studies between APAP and the regioisomer of AMAP in mice 
mainly conducted by Dr. Sidney Nelson’s group.  The lack of hepatotoxicity after AMAP 
at doses which are toxic with APAP was confirmed by several studies in various species 
(Tirmenstein and Nelson, 1989; Roberts et al., 1990; Holme et al., 1991; Pierce et al., 
2002). It was also indicated that there were less cytosolic and mitochondrial GSH 
depletion, reduced protein nitration and an absence of JNK activation after AMAP 
compared with APAP (Tirmenstein and Nelson, 1989; Myers et al., 1995; Abdelmegeed 
et al., 2013). Most importantly, AMAP and APAP resulted in comparable total cellular 
protein adducts formation while there were significantly more mitochondrial protein 
adducts formation after APAP (Tirmenstein and Nelson, 1989; Myers et al., 1995; Qiu et 
al., 2001).  Another important piece of evidence supporting the critical role of 
mitochondria is about the source of oxidant stress. Study from our lab reported an 
increase of both hepatic and mitochondrial GSSG but no changes in biliary GSSG levels 
(Jaeschke, 1990). As cytosolic GSSG is partially excreted into bile at physiology states, 
the absence of biliary GSSG excretion suggests that the elevated GSSG in the 
hepatocytes are restricted to organelles that do not release GSSG into the cytosol, e.g. 




accounted for the increase in the total GSSG content in the liver (Jaeschke, 1990). Of 
note, this also suggests that the oxidant stress does not come from the process of APAP 
metabolism. Although CYP450s catalyzes electron transfers during the reaction and is 
known to induce oxidative stress. However, under in vivo conditions, there is no direct 
evidence for oxidant stress during APAP metabolism (Smith and Jaeschke, 1989; Bajt et 
al., 2004). Further support for mitochondrial oxidant stress came from the observation 
that peroxynitrite was selectively generated in the mitochondria and acted as a critical 
mediator of APAP toxicity (Knight et al., 2002; Cover et al., 2005). Besides, loss of 
SOD2 in mitochondria in mice enhanced APAP-induced liver injury, and mitochondrial 
translocation of iron exacerbated the injury (Kon et al., 2010). 
The result of mitochondrial adducts formation after APAP is multifaceted. On one hand, 
binding of NAPQI to mitochondrial proteins like ATP synthase could directly lead to 
cessation of ATP production (Jaeschke, 1990). On the other hand, attack of mitochondrial 
proteins by NAPQI could impair mitochondrial respiration and initiate oxidative stress 
(Meyers et al., 1988). Specifically, the presumably damaged electron transfer chains 
(ETC) donate free electrons directly to O2, generating superoxide O2
−
 and other reactive 
oxygen and nitrogen species as discussed above. One critical downstream result of the 
initial oxidant stress is the activation of several signaling pathways especially JNK 
(Gunawan et al., 2006; Hanawa et al., 2008) through ASK1 (Nakagawa et al., 2008; Xie 
et al., 2015c), MLK3 (Sharma et al., 2012), GSK3β (Shinohara et al., 2010) and also 
RIP1/3( Ramachandran et al., 2013; Zhang et al., 2014). The activated/phosphorylated 
JNK translocates to the mitochondria and amplifies the early oxidant stress (Saito et al., 




mitochondrial membrane to elicit collapse of mitochondrial membrane potential and loss 
of the proton gradient. With that, the mitochondria are unable to maintain the osmolality 
and undergo oncotic swelling (Placke et al., 1987; Kon et al., 2004).  Several strategies 
that prevent the MPT have shown protective effects. Using cyclosporine A or 
NIM811which are pharmacological inhibitors of the MPT pore regulator cyclophilin D, 
APAP hepatoxicity was significantly reduced in vitro and in vivo (Kon et al., 2004; 
Masubuchi et al., 2005). Besides, APAP toxicity was significantly attenuated in 
cyclophilin D knockout mice (Ramachandran et al., 2011a). However, debio 025, an 
analog of cyclosporine A failed to provide protection (LoGuidice and Boelsterli, 2011). 
Although the accurate composition of MPT pores is still in dispute, its indispensable role 
in APAP hepatotoxicity has been confirmed.  
In the later phase of cell death after APAP, the opening of MPT pore and mitochondrial 
swelling cause release of mitochondrial intermembrane proteins, in particular apoptosis-
inducing factor (AIF) and endonuclease G (endoG), which are responsible for nuclear 
DNA fragmentation after APAP (Cover et al., 2005; Bajt et al., 2006; Bajt et al., 2011). 
Previous data demonstrated a lack of caspase contribution to DNA fragmentation after 
APAP as there was no caspase activation and a pan-caspase inhibitor Z-VAD-fmk did not 
protect against the injury (Lawson et al., 1999; Jaeschke et al., 2006). Although MPT 
results in AIF and endoG  translocation in the later phase, in the early phase, bax 
translocation to the mitochondrion is responsible for the release of AIF, endo G and 
second mitochondria-derived activator of caspases (smac) (Bajt et al., 2008). Therefore, it 
is not surprising to see an early but not lasting protection in Bax
-/-




et al., 2008). It looks like although the cells activate some of the apoptotic mechanisms, 



















1.3 Signaling pathways in APAP-induced hepatotoxicity 
 
The study of intracellular signaling pathways of APAP-induced hepatoxicity has sparked 
a continuous wave of publications in the recent decade and has filled in multiple 
knowledge gaps in this model. It started with the findings that both genetic deletion of c-
Jun N-terminal kinase (JNK) 2 and pharmacological inhibition by the JNK inhibitor 
SP600125 protected mice against APAP toxicity (Gunawan et al., 2006; Henderson et al., 
2007; Cubero et al., 2015). Although this was soon challenged by a similar study using a 
different mice strain (Bourdi et al., 2008),  subsequent observations that apoptosis-
signaling kinase 1 (ASK1) knockout mice were protected against APAP supports the 
conclusion that JNK is critical, as ASK1 is an upstream kinase of JNK (Nakagawa et al., 
2008). This protection by inhibiting ASK1 was later confirmed using an ASK1 specific 
inhibitor GS-459769 from Gilead Sciences, Inc. (Xie et al., 2015c). Furthermore, two 
other JNK inhibitors, leflunomide (LEF) which is an anti-rheumatic drug and D-JNK1 
which is a peptide inhibitor both alleviated APAP-induced liver toxicity in mice 
(Latchoumycandane et al., 2006; Henderson et al., 2007). Also, mice deficient in Mkp-
1which is a phosphatase of P-JNK displayed worse phenotype (Wancket et al., 2012). 
Although conflicting observations exist, the preponderance of data favors a deleterious 
effect by JNK (Cubero et al., 2015; Du et al., 2015).   
These initial studies stimulated the investigations of JNK in APAP-induced liver injury, 
and revealed possibilities of alleviating the injury by modulating signaling pathways in 
addition to the traditional antidote NAC (Saito et al., 2010). It was soon discovered that 
JNK is only part of the signaling network, as upstream players like glycogen synthase 




kinase 1(ASK1) were subsequently identified (Nakagawa et al., 2008; Shinohara et al., 
2010; Sharma et al., 2012) . As demonstrated by gene knockout or knockdown studies in 
mice, GSK3β and MLK3 are considered early regulators of JNK activation while ASK1is 
a late regulator maintaining the activation. Genetic deletion of any of the three genes 
significantly protected mice from APAP-induced liver injury (Nakagawa et al., 2008; 
Shinohara et al., 2010; Sharma et al., 2012). As both ASK1 and MLK3 are mitogen-
activated protein kinases (MAP3K), it is not surprising to see the attenuated activation of 
the MAPK namely JNK and alleviated injury after the blockade of ASK1 or MLK3 
(Ichijo et al., 1997; Lotharius et al., 2005). However, what is important is that ASK1, 
MLK3 and GSK3β are all redox-sensitive enzymes, and therefore the link between JNK 
and the upstream mitochondrial oxidant stress is established (Saitoh et al., 1998; Grimes 
and Jope 2001; Noguchi et al., 2005; Hong and Kim 2007; Lee et al., 2014). A player 
downstream of JNK was also identified, which is Sab (SH3 domain-binding protein that 
preferentially associates with Btk) (Win et al., 2011). Sab is a scaffold protein on the 
outer membrane of mitochondria. Immunoprecipitation indicated that JNK and Sab 
physically interacted with each other (Chambers et al., 2011; Win et al., 2011). Silencing 
or loss of Sab abrogated sustained JNK activation and translocation, and also 
significantly reduced hepatic injury (Win et al., 2011; Win et al., 2016). Recent study 
suggested that the interaction between JNK and Sab lead to SHP1 (also named PTPN6: 
protein tyrosine phosphatase, non-receptor type 6) dissociation from Sab, and 
subsequently SHP1 and DOK4 (docking protein 4)-dependent inactivation of Src protein. 
Src inactivation then triggered inhibition of mitochondrial electron transport chain and 




amplification loop beginning with and ending in JNK activation was suggested. 
Collectively, ASK1, MLK3 and GSK3β mediate JNK activation and phospho-JNK 
translocation to mitochondria in response to initial mitochondrial oxidant stress, while 
Sab interacts with JNK to mediate Src inactivation and ultimately mitochondrial ROS 
production.  
Despite a clearer picture of the signaling network, the specific role of JNK remains yet 
unanswered.  Several hypotheses have been proposed. First, JNK may induce Bax 
translocation to mitochondria. To test that, Bax-/- mice were exposed to APAP. At 6h, 
the injury was significantly attenuated as indicated by ALT. However, the protection was 
lost later on at 12h (Bajt et al., 2008). Therefore, the temporary protection by Bax 
deficiency does not fully explain the lasting protection in JNK knockout mice (Bajt et al., 
2008; Saito et al., 2010). Second, JNK may activate iNOS leading to increased 
peroxynitrite formation (Gunawan et al., 2006; Latchoumycandane et al., 2007; Hanawa 
et al., 2008).  However, the JNK inhibitor SP600125 failed to affect NO formation and 
iNOS inhibitor did not reduce the NO level after APAP (Saito et al., 2010). Third, the 
initial oxidative stress could elicit JNK activation and translocation to mitochondria 
which may be responsible for mitochondrial membrane permeability transition (MPT). 
Indeed, the JNK inhibitor SP600125 lowered the GSSG level after APAP, indicating the 
importance of JNK in promoting oxidative stress (Saito et al., 2010). Current thinking is 
that both GSH depletion and oxidant stress are necessary for the activation of JNK but 
not sufficient for the final injury, while either replenishing GSH repository or scavenging 




Although the weight of evidence generally favors a pathological role of JNK in APAP-
induced liver injury, studies with alternative results challenge the hypothesis and 
increased the complexity (Du et al., 2015). Among those, studies from multiple labs 
using JNK1 or 2 
-/- 
mice have demonstrated that these knockout mice are not protected 
against APAP toxicity (Henderson et al., 2007; Bourdi et al., 2008; Hanawa et al., 2008; 
Saito et al., 2010). Part of the reason for the disparities in toxicity is the inconsistent 
genetic background of the mice used across studies (Bourdi et al., 2011). On the other 
hand, JNK1 and JNK2 most likely compensate for each other and therefore selective 
elimination of either one was not completely protective (Hanawa et al., 2008; Du et al., 
2015).  
Even though JNK is now generally considered essential in the progression of injury, it is 
still counterintuitive that one single molecule acts as an on/off switch for the whole injury 
process. In agreement with that, recent data suggested a protein kinase C (PKC)-mediated 
while JNK-independent pathway contributing to the pathogenesis of APAP toxicity 
(Saberi et al., 2014). In addition to the PKC pathway, receptor-interacting protein kinase 
1 and 3 (RIP1 or RIP3) also profoundly contribute to the injury. Both genetic deletion 
and knockdown of RIP3 protected the mice at early but not late time points, suggesting 
that RIP3 is an early injury mediator after APAP.  Besides, pharmacological interventions 
using RIP1 inhibitor necrostatin-1 or RIP3 inhibitor dabrafenib significantly alleviated 
injury (Sharma et al., 2012; Li et al., 2014). Although conflicting data exist, JNK is not 
the sole player in APAP-induced liver injury.  
Although currently necrosis is a widely-accepted mode of cell death after APAP, it was 




arguments suggest a minor role of apoptosis. First, histological evaluations demonstrated 
extensive cell swelling and massive cell content release after APAP, with very few 
apoptotic cells (Gujral et al., 2002). Additionally, in fast mice there was no significant 
caspase activation after APAP and caspase inhibitors did not protect against the injury 
(Lawson et al., 1999; Gujral et al., 2002; Williams et al., 2010). Although transient 
caspase activation was observed in fed Swiss Webster mice treated with APAP, the 
overall cell death was still apoptotic and did not fundamentally change (Williams et al., 
2011b). Consistently, as DNA fragmentation is induced by Endo G and AIF rather than 
caspases, APAP-induced hepatic injury was not affected by caspase inhibitor treatment 














1.4 Treatment strategies for APAP-induced liver injury 
 
Investigations of APAP-induced hepatotoxicity over the past decades expanded our 
understanding of the injury mechanisms, and more importantly provided new treatment 
strategies. Although in the clinic N-acetylcysteine (NAC) remains the most convenient 
and economic antidote for APAP overdose nowadays, with APAP toxicity being not only 
a single OTC drug toxicity but also a classical model of DILI and ALF, the exploration of 
novel therapeutic options is especially enlightening. 
1.4.1 Enhance antioxidant defenses 
One major protective mechanism of NAC is to enhance the antioxidant defenses. The 
popularity of NAC dates back to four decades ago largely due to the excellent efficacy 
and easy administration given the commercially available dosage forms (Prescott et al., 
1977; Vale et al., 1981; Polson and Lee 2005). Furthermore, the Rumack-Matthew 
nomogram delineates the relationship between serum concentrations of APAP and hours 
after ingestion to assists better decision of NAC treatment in clinic (Rumack and 
Matthew, 1975; Rumack et al., 1981).  
Mechanistically, NAC serves as a reservoir of cysteine residues and provides this rate-
limiting substrate to stimulate the biosynthesis of the tri-peptide glutathione (Lauterburg 
et al., 1983). In vivo, N-acetyl-L-cysteine but not the isomer N-acetyl-D-cysteine 
stimulated GSH synthesis, and therefore only the former was able to alleviate the injury 
after APAP (Corcoran and Wong, 1986). With NAC replenishing the GSH pool after 
APAP, NAPQI could be detoxified through conjugation with GSH. Therefore, cellular 




treatment regimens which reduce covalent binding were most effective in attenuating 
liver injury after APAP (Corcoran et al., 1985). However, NAC needs to be administered 
in patients early after APAP overdose. 
By restoring the GSH level, NAC also scavenges the reactive oxygen and nitrogen 
species after APAP (Knight et al., 2002). These interferences on early cellular events 
after APAP are sufficient to explain the efficacy of NAC when given during or soon after 
APAP metabolism. However, in some cases, late treatment of NAC still improves the 
patient outcome, indicating that additional protective mechanisms are operative (Harrison 
et al., 1990; Saito et al., 2010). For that matter, a third mechanism was proposed, 
suggesting that excess NAC was able to improve the energy supply by providing 
substrates to the Krebs cycle (Saito et al., 2010). By comparing GSH and NAC treatment 
after APAP, it was recognized that the most effective strategy to attenuate the injury is to 
supply excessive cysteines for GSH and simultaneously amino acids for energy 
production in the Krebs cycle (Saito et al., 2010). In summary, NAC replenishes GSH 
pool to scavenge NAPQI formation, prevents insults to proteins and also reduces ROS 
and RNS formation. In addition, NAC provides energy substrates for the Krebs cycle.  
Methionine can be converted to cysteine and therefore promotes GSH biosynthesis 
similar to NAC. Evidence indicates that methionine is comparable in efficacy as NAC, 
although the latter is more commonly prescribed (Brok et al., 2006). Other antidotes with 
similar mechanisms include cysteamine and dimercaprol, which are less preferable based 
on patient outcome (Crome et al., 1976; Hughes et al., 1977; Vale et al., 1981; Brok et al., 




Paradote in UK. However, it was discontinued to the unpleasant odor from the sulfur and 
higher costs. 
In addition to the effort of promoting GSH resynthesis, other antioxidants have also been 
tested and have shown protection. Metallothionein is a low molecular weight protein rich 
in cysteines (Coyle et al., 2002). Zn-induced metallothionein was able to significantly 
alleviate APAP toxicity in mice without interfering with the metabolism, as 
metallothionein scavenged NAPQI when GSH was depleted (Saito et al., 2010). Also, 
resveratrol, a polyphenol small molecule antioxidant, protected against APAP-induced 
liver injury even as a posttreatment possibly through directly scavenging peroxynitrite 
and preventing DNA fragmentation (Fremont 2000; Du et al., 2015). On the other hand, 
attempts to manipulate lipid peroxidation by extra supply of vitamin E failed to achieve 
any protective effect, suggesting that LPO is not a relevant mechanism of injury (Knight 
et al., 2003).  
1.4.2 Target signaling pathways 
Like current cancer therapies which focus on several important receptor tyrosine kinases, 
targeting signaling pathways also emerges as potential treatment strategies for APAP 
overdose. The majority of the effort was devoted to the MAPK pathway, and several 
pharmacological inhibitors have been tried in this model. Specifically, inhibitors of 
apoptosis signaling kinase 1(ASK1), c-Jun N-terminal kinase (JNK), receptor interacting 
protein (RIP) 1 or 3 are protective after APAP in mice as discussed in 1.2.4. Importantly, 
data have shown the lack of interference on liver regeneration by inhibiting ASK1 (Xie et 




not. Comparison of the JNK inhibitor SP600125 with NAC in primary human 
hepatocytes indicates that, the JNK inhibitor SP600125 is partially protective against 
APAP as a 3h-posttreatment while NAC is completely protective at 6h after APAP, 
suggesting a superior efficacy of NAC (Xie et al., 2014). Similarly, in mice the protection 
of ASK1 inhibitor but not NAC is lost at 3h post APAP (Xie et al., 2015c). Thus, 
targeting events upstream of JNK activation including scavenging mitochondrial ROS is 
necessary and could potentially provide better protection than modulating MAPK 
pathway (Du et al., unpublished data). 
1.4.3 Stimulate autophagy 
Autophagy is a conservative catabolic process which degrades cellular contents and 
recycles them for synthesis of macromolecules or ATP (Mizushima and Komatsu 2011). 
Previous findings demonstrated that an autophagy inducer rapamycin prevented, while 
autophagy inhibitors 3-methyladenine or choloroquine exacerbated APAP-induced 
toxicity in vitro and in vivo, suggesting a protective role of autophagy (Ni et al., 2012; Ni 
et al., 2012). The reason for the protection is that autophagy selectively removes damaged 
mitochondria and therefore attenuates the toxicity (Ni et al., 2012a &b & 2013). 
Specifically, targeting PINK1-Parkin-mediated autophagy could be a therapeutic option 
for APAP overdose (Williams 2015 a&b). Also, broad spectrum protein kinase C (PKC) 
inhibitors protected against APAP in mice by upregulating AMPK-mediated autophagy 
(Saberi et al., 2014; Du et al., 2015). Together, enhancing autophagy represents a 
potential therapeutic strategy which promotes the clearance of impaired mitochondria and 




1.4.4 Promote liver regeneration 
As liver is a regenerative organ, stimulation of liver regeneration has always been a 
potential treatment approach for liver diseases. Previous studies have demonstrated the 
importance of liver regeneration after APAP administration in mice, and several 
mediators including VEGF, IL-6, TNF-α and beta-catenin activation are shown to 
promote liver regeneration (Chiu et al., 2003; James et al., 2003; Donahower et al., 2006; 
Apte et al., 2009; Bhushan et al., 2014). Also, the increase of serum alpha-fetoprotein, 
which is indicative of liver regeneration, correlated with favorable outcomes in patients 
(Schmidt and Dalhoff, 2005). Importantly, exogenous administration of stem cell factors 
(SCF) and human recombinant VEGF, which stimulates liver regeneration, managed to 
attenuate the injury after APAP (Hu and Colletti et al., 2008; Donahower et al., 2010). 
With that, enhancing liver regeneration holds promise as a therapeutic option for APAP 
overdose in the clinic. 
1.4.5 Others 
In additional to the discussed therapeutic strategies, pharmacological interventions on 
mitochondria membrane permeability transition (MPT) have shown some effect. 
Cyclosporine A and NIM 811are able to attenuate APAP hepatotoxicity, which is 
consistent with the reduced injury in cyclophilin D knockout mice (Kon et al., 2004; 
Masubuchi et al., 2005; Ramachandran et al., 2011a). Also, modulating mitochondrial 
fission by inhibiting DRP1 (Dynamin-related protein 1) prevents APAP toxicity in vitro, 
suggesting the relationship between mitochondria dynamics and hepatocyte cell death 




1.5 Current experimental models of APAP-induced hepatotoxicity 
 
With the popularity of acetaminophen as a model of DILI, the mechanisms of injury have 
been extensively explored in a spectrum of in vitro and in vivo models. Overall, 
disparities of human relevancy exist among different models. However, there is no 
perfect model for APAP hepatotoxicity, and each model illuminates cellular events to a 
certain degree. A summary of advantages and disadvantages of these experimental 
models can be found in table 7.2.1.  
1.5.1 Animal models 
In the clinic, acetaminophen-induced liver injury is a fulminant, dose-dependent and 
predictable type of DILI (Jaeschke, 2015). The reproducibility of these characteristics in 
the mouse readily explains its prevalence as an experimental model for APAP studies. 
Consequently, the majority of the understanding about APAP-induced liver injury in the 
past few decades was developed in mice, and most of the understanding was confirmed in 
humans by measuring mechanistic biomarkers in plasma samples from APAP overdose 
patients and in primary human hepatocytes (McGill et al., 2012a; McGill et al., 2014c; 
Xie et al., 2014). Despite these advantages of the mouse model, a few limitations still 
exist. First, there are gender differences in mice which are not obvious in human. Studies 
revealed the resistance of female mice to APAP and this was partially explained by a 
faster GSH recovery (Franc et al., 1997; Du et al., 2014). Second, the progression of 
injury is accelerated in mice compared with humans. In mice, significant liver injury as 
indicated by ALT release is observed starting from 2h after APAP overdose with peak 




onset of injury in human is delayed and the injury culminates between 24-48 h after 
APAP exposure (Singer et al., 1995; Larson 2007; McGill et al., 2012a). Different 
administration routes in human and mice are partially responsible for the disparities in 
injury progression, as mice are administered with dissolved APAP saline while patients 
ingest APAP tablets which take extra time for absorption.  
Although the rat is a common species in toxicology studies as required by regulatory 
agencies such as the FDA and EPA, it is not a relevant model for APAP-induced liver 
toxicity. Consistently, rats are resistant to APAP at even 2g/kg. Also, rats have 
significantly less mitochondrial protein adduct formation and oxidative stress, and there 
is no JNK activation and P-JNK translocation to mitochondria (McGill et al., 2012b). 
However, the usage of rats to test the hepatoprotection of herbal therapeutics is 
commonly seen. Most of the time, the ALT release in APAP-treated rats are close to 
control rats, making it difficult to test any reduction of ALT by the herbal products 
(Jaeschke et al., 2011). Thus, the rat is not a relevant model for APAP toxicity studies.  
Studies of APAP-induced hepatotoxicity are also conducted in other animal species, 
including hamster, zebrafish, cats, dogs and others (Tee et al., 1986; Allen, 2003). 
However, the relevancy of the injury pattern for human has not been established and may 
be questionable. 
1.5.2 Primary human and mouse hepatocytes 
In vivo models are most ideal for systemic toxicity testing. However, in vitro models are 
also informative when the mechanisms of actions are due to hepatocytes but not other 




Among all in vitro models, primary human hepatocytes (PHHs) remain the gold standard 
of toxicity testing which allow experimental interventions (Godoy et al., 2013). Needless 
to say, PHH has a full repertoire of drug metabolizing enzymes and transporters, and it is 
an in vitro model closest to human livers (Wilkening et al., 2003). Generally, PHHs are 
isolated from liver tissues of individual patient donor, which renders PHHs susceptible to 
interindividual variability in drug responses. The first hepatocyte isolation method was 
established more than 40 years ago and the current protocol follows a similar two-step 
collagenase digestion method (Bojar et al., 1976; Seglen, 1976; Strom et al., 1982).   
Despite the advantages of PHH, several limitations exist, and continuous efforts have 
been made to improve the availability, convenience and human relevance of PHHs. The 
first limitation is that PHHs are available on an unpredictable basis depending on the liver 
donors, and therefore the duration of study is considerably prolonged (Xie et al., 2014). 
Cryopreservation of isolated PHHs was introduced for this reason, and the frozen PHHs 
are ready to use after thawing. However, the viability of cryopreserved PHHs depends on 
the PHH quality before processing as well as the freezing plus storage procedures, and 
the viability is generally low.  
Another disadvantage of PHH is the progressive cell dedifferentiation, mainly reflected 
by the loss of cell polarity and alterations of drug metabolizing enzymes or transporters. 
As these features are critical for hepatocyte functionality, several approaches are adapted 
to overcome these issues. First, for short-term toxicity studies, it is recommended to 
perform the experiment soon after proper attachment of PHHs to avoid the gradual 
dedifferentiation process especially the loss of Cytochrome P450 enzyme expression (Xie 




been shown to prevent the dedifferentiation to some degree (Godoy et al., 2013; 
Schyschka et al., 2013).  A more widespread application of cryopreserved PHHs relies on 
the improvement of all these determinants.  
Similar to PHHs, precision–cut liver slices which are liver sections from human liver 
donors, have also been used for APAP toxicity studies. The intact tissue architecture, 
expression of drug metabolizing enzymes and transporters, as well as the presence of 
non-parenchymal cells could provide new insights in addition to PHHs (Hadi et al., 2013).  
As an in vitro counterpart of mice, primary mouse hepatocytes (PMHs) are also 
frequently used. The PMH is not only a model to confirm cellular events in vivo, but also 
a tool to investigate parenchymal cell responses or non-inflammatory activities to APAP. 
As the role of sterile inflammation after APAP has been a highly controversial topic in 
recent years, primary hepatocytes serve as a reference model to test any potential artifacts 
(Jaeschke et al., 2012). If sterile inflammation does play a role during the injury 
progression after APAP, any blockade on sterile inflammation or non-parenchymal cells 
should not affect APAP-induced cell death in PMHs. On the other hand, if the same 
protection against APAP in vivo is reproducible in PMHs, then most likely the protection 
is not due to modulating sterile inflammation (Xie et al., 2013).  
1.5.3 Hepatoma cell lines  
As PMH isolation requires mouse liver perfusion, more accessible alternatives are 
hepatoma cell lines, including HepaRG, HepG2, Hep3B and Huh7 (Jaeschke et al., 2011; 
McGill et al., 2011; Jaeschke et al., 2013). HepaRG cells are bipotent hepatoma cells 




hepatocytes and biliary epithelial cells (Parent et al., 2004; Cerec et al., 2007; Guillouzo 
et al., 2007). Most importantly, the HepaRG cell expresses sufficient amount of CYP450s 
for drug metabolism and therefore is a suitable model for drug toxicity testing (Guillouzo 
et al., 2007; Kanebratt and Andersson, 2008; McGill et al., 2011). The key cellular events 
and time courses after APAP in HepaRG cells are similar to human (McGill et al., 2011; 
Xie et al., 2015a). Although APAP does not activate JNK in HepaRG cells and the cells 
are not responsive to JNK inhibitor SP600125, the cell line provides an experimentally 
convenient and relevant model for APAP hepatotoxicity studies (McGill et al., 2011; Xie 
et al., 2014). In contrast, a number of hepatoma cells including HepG2, Hep3B, Huh7 
lack CYP450 enzyme expression and have limited biotransformation properties. 
Therefore, these cell lines are unsuitable to study APAP-induced liver cell death 
(Jaeschke et al., 2011; Jaeschke et al., 2011). 
1.5.4 Clinical samples of APAP overdose patients 
Although APAP overdose is the most frequent cause of acute liver failure in the US, liver 
biopsies are not recommended due the risk of bleeding in patients (Lee, 2012). With that, 
blood samples from consented APAP overdose patients are being used. Although no 
experimental interventions are permitted, studies using patient blood samples have 
allowed significant process especially on mechanistic biomarker identification (McGill 
and Jaeschke 2014). A spectrum of APAP biomarkers including HMGB1 (Antonie et al., 
2009& 2012), keratin-18 (Antonie et al., 2009& 2012), micro RNAs (Ward et al., 2014; 
Vliegenthart et al., 2015), APAP-protein adduct (Daven et al., 2006; McGill et al., 2013), 
mtDNA, nuclear DNA (McGill et al., 2012a &2014c), glutamate dehydrogenase (GDH) 




(McGill et al., 2014b), glycodeoxycholic acid (Woolbright et al., 2014) and others have 
all demonstrated a correlation with the injury and with the clinical outcome in most cases. 
The continuous search for superior biomarkers especially progenitor biomarkers comes 
from the fact that traditional clinical endpoints of liver injury like ALT do not predict 
who survives or recovers and who dies. Future exploration of potential biomarkers still 















1.6 Specific aims of the dissertation 
Specific Aim 1 - Investigate the time course and dose-response of APAP toxicity in 
primary human hepatocytes 
The time course (0-48h) and dose response (1-20 mM) of APAP-induced cell death will 
be studied in primary human hepatocytes. In these studies, it will be investigated if key 
events observed in mouse hepatocytes and HepaRG cells, i.e.  GSH depletion, protein 
adducts formation, mitochondrial dysfunction and oxidant stress are critical for cell 
necrosis in PHH.  
Specific Aim 2 – Investigate the involvement of ASK1 and JNK in the 
pathophysiology of APAP-induced cell death 
The importance of JNK-ASK1 pathway has been documented in the mouse model. Thus, 
the objective is to assess if this pathway is also critical in human hepatocytes. The 
activation of this pathway will be evaluated using western blotting for P-JNK. In addition, 
mitochondrial translocation of P-JNK will be assessed. The pathophysiological relevance 
will be tested using pharmacological inhibitors of ASK1 and JNK and by gene 
knockdown experiments. 
Specific Aim 3 – Investigate the effect of cell culture oxygen tension on APAP-
induced cell death in primary human hepatocytes. 
Our lab has demonstrated that the artificially high oxygen concentration in incubators 
using room air (21% oxygen) leads to enhanced oxidant stress and accelerated cell death 






















































This section is adapted from Xie et.al (2014), “Mechanisms of acetaminophen-induced 
cell death in primary human hepatocytes”, Toxicology and Applied Pharmacology, 






Acetaminophen (APAP) overdose is the most prevalent cause of drug-induced liver 
injury in western countries. Numerous studies have been conducted to investigate the 
mechanisms of injury after APAP overdose in various animal models; however, the 
importance of these mechanisms for humans remains unclear. Here we investigated 
APAP hepatotoxicity using freshly isolated primary human hepatocytes (PHH) from 
either donor livers or liver resections. PHH were exposed to 5 mM, 10 mM or 20 mM 
APAP over a period of 48 h and multiple parameters were assessed. APAP dose-
dependently induced significant hepatocyte necrosis starting from 24 h, which correlated 
with the clinical onset of human liver injury after APAP overdose. Interestingly, cellular 
glutathione was depleted rapidly during the first 3 h. APAP also resulted in early 
formation of APAP-protein adducts (measured in whole cell lysate and in mitochondria) 
and mitochondrial dysfunction, indicated by the loss of mitochondrial membrane 
potential after 12 h. Furthermore, APAP time-dependently triggered c-Jun N-terminal 
kinase (JNK) activation in the cytosol and translocation of phospho-JNK to the 
mitochondria. Both co-treatment and post-treatment (3 h) with the JNK inhibitor 
SP600125 reduced JNK activation and significantly attenuated cell death at 24 h and 48 h 
after APAP. The clinical antidote N-acetylcysteine offered almost complete protection 
even if administered 6 h after APAP and a partial protection when given at 15 h. 
Conclusion: These data highlight important mechanistic events in APAP toxicity in PHH 
and indicate a critical role of JNK in the progression of injury after APAP in humans. 







Acetaminophen (APAP; paracetamol) is widely used as an analgesic and antipyretic drug. 
At therapeutic doses, it is considered effective and safe but an overdose can cause severe 
liver injury, liver failure and even death (Larson, 2007). Currently, APAP is the leading 
cause of drug-induced liver failure in the US and UK (Lee, 2012). Considerable progress 
has been made in the understanding of the mechanisms of injury after APAP overdose in 
animal models (Jaeschke et al., 2012). Although most of the drug is conjugated with 
glucuronic acid or sulfate and excreted, a small fraction is metabolized by cytochrome 
P450 enzymes to a reactive metabolite, presumably N-acetyl-p-benzoquinone imine 
(NAPQI). NAPQI can be scavenged through conjugation with glutathione (GSH) and can 
react with protein sulfhydryl groups to form adducts ( Mitchell et al., 1973). It is thought 
that protein adducts, especially in mitochondria, cause mitochondrial dysfunction and an 
early oxidant stress, which initiates the activation of various MAP kinases ( Jaeschke et 
al., 2012). Ultimately, the activities of different kinases converge to phosphorylate c-jun-
N-terminal kinase (P-JNK), which then translocates to the mitochondria and amplifies the 
oxidant stress and peroxynitrite formation ( Hanawa et al., 2008 and Saito et al., 2010a). 
This mitochondrial oxidant stress leads to the opening of the membrane permeability 
transition (MPT) pore with collapse of the membrane potential and cessation of ATP 
synthesis. In addition, the MPT causes mitochondrial matrix swelling, with rupture of the 
outer membrane and the release of intermembrane proteins, such as endonuclease G and 
apoptosis-inducing factor, which translocate to the nucleus and induce DNA 
fragmentation (Jaeschke et al., 2012). Together, these events result in cell necrosis 




After the early mechanistic insight into APAP hepatotoxicity in mice leading to the 
development of the first clinical antidote N-acetylcysteine (NAC) (Prescott et al., 1977), 
no further therapeutic intervention has been developed during the last 35 years. One of 
the main reasons is limited understanding of the human pathophysiology, which makes it 
difficult to directly extrapolate potential therapeutic targets in mice to humans. However, 
some progress has been made recently. In the metabolically competent human hepatoma 
cell line HepaRG, APAP-induced protein adducts formation, mitochondrial dysfunction 
and oxidant stress preceded cell necrosis at 24–48 h (McGill et al., 2011). In patients with 
APAP overdose, high levels of protein adducts have been detected in serum (Davern et 
al., 2006 and Muldrew et al., 2002). Furthermore, evidence for mitochondrial damage, i.e. 
the leakage into serum of the mitochondrial matrix enzyme glutamate dehydrogenase 
(GDH) and mitochondrial DNA, were measured in patients with liver injury (McGill et 
al., 2012a). The rise of serum acylcarnitines reflected mitochondrial dysfunction in mice; 
however, this effect was not observed in humans because of the suppression by the 
standard of care NAC treatment (McGill et al., 2014b). In addition, cell death markers 
and damage associated molecular patterns found in mice, such as high mobility group 
box 1 protein, microRNA-122, cytokeratin-18, nuclear DNA fragments, and 
argininosuccinate synthetase, were also observed in serum of patients (Antoine et al., 
2012, McGill et al., 2012a, McGill et al., 2014a and Starkey Lewis et al., 2011). Despite 
these similarities in cellular responses to APAP overdose in mice and in humans, detailed 
signaling mechanisms of APAP-induced cell death in human hepatocytes remain unclear. 
A better understanding of these events is critical for development of any additional 




mechanisms of hepatotoxicity of APAP in freshly isolated primary human hepatocytes 
(PHH). Specifically, we wanted to determine critical but as yet unexplored events in PHH 
such as mitochondrial protein binding, mitochondrial dysfunction and mitochondrial 
translocation of P-JNK. Our data show similarities but also essential differences to mouse 
hepatocytes, some of which may explain the delayed toxicity in humans and PHH. 
 
2.3 Materials and methods 
 
Isolation of primary human hepatocytes 
All human tissues were obtained with informed consent from each patient, according to 
ethical and institutional guidelines. The study was approved by the University of Kansas 
Medical Center Institutional Review Board. A summary of medical information of donors 
is provided in Table 1. No donor tissue was obtained from executed prisoners or other 
institutionalized persons. All liver specimens were obtained in accordance with a Human 
Subject Committee approved protocol from patients undergoing a hepatic resection 
procedure or from donor organs. Liver specimens were obtained from the hospital 
operating room and placed in a sterile container that contains either cold sterile saline or 
cold University of Wisconsin's (UW) solution. The liver specimens were then placed in a 
secondary container with ice and transported back to the cell isolation lab. Once in the lab, 
all procedures were then performed in a biological safety cabinet using aseptic technique. 
A pan of ice was placed in the biological safety cabinet and covered by a plastic bag and 
then a sterile field was placed over the bag. The liver specimen was then placed on top of 




the tissue was perfused with cold EMEM (Mediatech cat # 15-010-CM) containing 
25 mM HEPES buffer (Mediatech cat # 25-060-CI) to determine which vessels provide 
the most uniform perfusion of the tissue. The catheters were then secured into the vessels 
either by sutures or surgical grade glue. All remaining major vessels on the cut surfaces 
were closed with sutures and/or surgical grade glue. The liver tissue was then placed in a 
sterile plastic bag and connected to a peristaltic pump with the flow rate dependent on the 
number of catheters and size of tissue. The bag containing the tissue was placed in a 
water bath at 37 °C and the tissue was perfused with calcium, magnesium and phenol red 
free HBSS (Hyclone cat # SH30588.02) containing EGTA (1.0 mM) without 
recirculation for 10–15 min. The EGTA chelates calcium which leads to the separation of 
cell junctions and helps to remove any residual blood. The liver specimen was then 
perfused for 8–10 min using HBSS without EGTA to flush residual EGTA from the 
tissue. Finally, the liver specimen was perfused with EMEM containing 0.1 mg/ml of 
collagenase (VitaCyte cat# 001-2030) and 0.02 mg/ml of protease (VitaCyte cat# 003-
1000) which was recirculated as long as needed (18–30 min.) to complete the digestion. 
All perfusion solutions were maintained at 37 °C via a water bath. Perfusion of the 
specimen was stopped when the liver tissue began to show fissures and separation from 
the liver capsule. The liver tissue was then removed from the plastic bag and placed in a 
sterile plastic beaker that contains ice-cold EMEM + 25 mM HEPES. The specimen was 
then gently chopped with sterile scissors to release hepatocytes. The cell suspension was 
filtered through sterile gauze-covered funnels to remove cellular debris and clumps of 
undigested tissue. Hepatocytes were isolated from the other cell types in the suspension 




the centrifugation steps were repeated 2 more times using cold EMEM + 25 mM HEPES 
to re-suspend the hepatocytes after each spin. After three washes in EMEM + 25 mM 
HEPES, the hepatocytes were re-suspended in cold Williams' Medium E (Life 
Technologies cat # A12176-01 supplemented with l-Glutamine (2 mM) (Life 
Technologies cat # 35050-061), HEPES (10 mM), insulin (10–7 M) dexamethasone (10–
7 M), penicillin (100 U/ml), streptomycin (100 μg/ml) and amphotericin B (0.25 μg/ml). 
Cell viability was assessed by trypan blue exclusion and cell number was determined by 
using a hemocytometer viewed through an inverted microscope. Viabilities were 
expressed as a percentage of the total cell number. The hepatocytes were brought to a 
concentration of 0.5 × 10
6
 cells/ml in Williams' Medium E, as described above, plus 5% 
bovine calf serum. The hepatocytes were then seeded on collagen coated plates and 
allowed to attach in a humidified 37 °C, 5% CO2incubator for 2–12 h and then the 
medium was changed to serum free Williams' Medium E supplemented as described. 
Primary human hepatocytes experiments 
Approximately 3 h after being seeded on collagen-coated dishes, cells were washed with 
sterile phosphate-buffered saline (PBS) and treated with APAP dissolved in Hepatocyte 
Maintenance Medium (Lonza, Walkersvill, MD) supplemented with insulin, 
dexamethasone, and gentamicin/amphotericin-B. Due to the limited number of 
hepatocytes obtained from each isolation procedure it is not possible to perform a 
complete set of assays on each batch of hepatocytes. We did not specifically assign 
patients to certain experiments. However, for every batch of cells, we measured ALT 
release of hepatocytes 24 and 48 h after 10 mM APAP to make sure the cells are 




Germany) dissolved in dimethyl sulfoxide (DMSO) was added to the cell culture medium 
to achieve a final concentration of 10 μM, either at the same time as APAP treatment, or 
3 h afterwards. For caspase inhibition experiments, cells were co-treated with 20 μM of 
Z-VD-fmk (generous gift from Dr. S.X. Cai, Epicept, San Diego, CA) and APAP. For N-
acetylcysteine (NAC) treatment, NAC was dissolved in H2O and then added to the 
culture medium at a series of time points after APAP to achieve the final concentration of 
20 mM. 
APAP-protein adducts measurement 
APAP-protein adducts were measured in total cell homogenate and in mitochondria. 
Briefly, hepatocytes or isolated mitochondria were lysed in 10 mM sodium acetate buffer, 
pH 6.5, by brief sonication or several cycles of freeze–thaw, respectively, and the lysates 
were filtered through a size exclusion column (Biospin-6 columns, Bio-Rad Laboratories, 
Hercules, CA) to remove low molecular weight compounds. The purified proteins were 
then digested overnight with proteases. Proteases were precipitated with an 
acetone/methanol mixture and pelleted, and the supernatants evaporated to a residue. The 
residue was then dissolved in 50 μL sodium acetate buffer and subjected to high pressure 
liquid chromatography with electrochemical detection (HPLC-ECD) of protein-derived 
APAP-cysteine (McGill et al., 2013 and Muldrew et al., 2002). Protein in the lysates was 
measured using the bicinchoninic acid assay (BCA). 
Biochemical assays 
ALT levels were determined using an ALT reagent kit (Pointe Scientific, MI). GDH 




substrate, caspase-3 activity was measured as previously described in detail (Jaeschke et 
al., 1998). A modified method of the Tietze assay was carried out to measure cellular 
glutathione levels as described (Jaeschke and Mitchell 1990). To detect the mitochondrial 
membrane potential, JC-1 Mitochondrial Membrane Potential Kit (Cell Technology, 
Mountain View, CA) was used as described in detail (Bajt et al., 2004) 
PI staining 
PHH were allowed to adhere on glass bottom dishes for 3 h, followed by 10 mM APAP. 
The medium was removed after 24 h and cells were stained with 500 nM of propidium 
iodide (Invitrogen) for 5 min. Nuclei were stained with 4′,6-diamidino-2-phenylindole 
(DAPI) and images were recorded with a fluorescence microscope. 
Isolation of subcellular fractions and Western blotting 
Mitochondria and cytosolic fractions were isolated from cell lysates using differential 
centrifugation as described (Cover et al., 2005). Standard Western blotting was 
performed using a rabbit anti-JNK antibody and a rabbit anti-phospho-JNK antibody 
(Cell Signaling Technology, Danvers, MA). 
HepaRG cells 
HepaRG cells were differentiated and treated as described (McGill et al., 2011). 
Statistics 
All results were expressed as mean ± standard error (SE). Comparisons between multiple 
groups were performed with one-way ANOVA followed by post hoc Student–Newman–









APAP induces necrotic cell death in PHH 
We evaluated the toxicity of APAP in freshly isolated PHH by performing a time course 
study with 5 mM and 10 mM APAP. APAP resulted in significant cellular ALT release 
into the culture medium starting from 24 h with a progressive further increase up to 48 h 
(Fig. 2.4.1A). The injury was dose-dependent (Fig. 2.4.1B). PI staining of the nuclei 
confirmed the necrotic cell death (Fig. 2.4.1C). Furthermore, no increase in caspase-3 
activity was detectable in APAP-treated PHH cells at 24 h (data not shown). 
The total number of cell isolations for this manuscript was 44 with the donor patient 
information listed in Table 2.4.1. For each batch, cell injury was determined at 24 and 
48 h after APAP exposure and compared to cell death in controls. Fig. 2.4.2A 
demonstrates the variability in the cell death response between different batches of cells. 
In addition, the groups were separated into cells from male and female donors (Fig. 
2.4.2B). Our results do not indicate a statistically significant gender difference in toxicity 
in response to APAP exposure. Furthermore, GSH depletion of cells from 7 individual 
donors is shown in Fig. 2.4.2C. Together, these data demonstrate a limited inter-




APAP triggers GSH depletion, mitochondria dysfunction and protein adducts 
formation in PHH 
APAP is metabolized to the electrophile NAPQI, which can react with the sulfhydryl 
groups of cysteine in GSH or cellular proteins. Exposure to 10 mM APAP reduced 
cellular GSH levels by > 70% within 3 h, followed by further depletion over the next 
20 h (Fig. 2.4.3A). Measurement of the mitochondrial membrane potential with the JC-1 
assay revealed significant mitochondrial dysfunction and loss of mitochondrial 
membrane potential between 6 and 15 h after APAP (Fig. 2.4.3B). Protein adducts in the 
cells were formed mainly during the first 6 h, with no further increase up to 15 h (Fig. 
2.4.3C). Interestingly, protein adducts in mitochondria did not increase during the first 
3 h, i.e. before GSH was depleted by 70%. However, mitochondrial adduct levels 
dramatically increased between 3 and 6 h (Fig. 2.4.3D). These time course experiments 
revealed a sequence of events in PHH after APAP exposure that includes rapid GSH 
depletion and protein adduct formation, with mitochondrial protein adduct formation and 
mitochondrial dysfunction occurring later, only after extensive GSH depletion. 
APAP causes JNK activation and mitochondrial translocation in PHH 
JNK activation and the mitochondrial translocation of phospho-JNK (P-JNK) have been 
well established as a second hit in mouse hepatocytes to amplify the initial oxidative 












Figure 2.4.1  APAP Induces Cell Death In Primary Human Hepatocytes (PHH). 
Cells were treated with 5 mM or 10 mM APAP over a period of 48 h. (A) Time course of 
toxicity over 48 h, as indicated by percentage of alanine aminotransferase (ALT) activity 
found in the culture medium, (B) dose–response of APAP toxicity at 24 h after treatment. 
(C) Necrotic cell death as indicated by nuclear PI staining after 24 h after 10 mM APAP 
exposure. The nucleus was stained with DAPI. Data in A and B represent mean ± SE of 





Figure 2.4.2  Inter-individual variation of ALT and GSH levels in primary human 
hepatocytes.  
(A) ALT release from hepatocytes isolated from 44 patients. Each batch of cells 
(individual patient) were either untreated (0), or exposed to 10 mM APAP for 24 and 48 
h. (B) ALT release from hepatocytes isolated from male and female patients 24 and 48 h 
after 10 mM APAP. (C) GSH levels of hepatocytes from each individual (n = 7) at 0 and 






Figure. 2.4.3 APAP triggers GSH depletion, mitochondria dysfunction and protein 
adduct formation in PHH.  
(A) Time course of cellular glutathione depletion after 10 mM APAP. (B) Loss of 
mitochondria membrane potential over 24 h after 10 mM APAP, as indicated by decrease 
of red/green fluorescence ratio using the JC-1 assay. APAP-protein adduct formation (C) 
in the whole cell and (D) in the mitochondria fraction over 15 h after 10 mM APAP. Data 
represent mean ± SE from experiments using cells from 3 to 8 donors. * P < 0.05 






Figure. 2.4.4 APAP leads to cellular JNK activation in PHH and phospho-JNK 
translocation to the mitochondria.  
(A) Time course of JNK activation in whole cell homogenate after 10 mM APAP and (B) 
Densitometry. (C) JNK activation in the cytosol and phospho-JNK translocation to the 
mitochondria and (D) Densitometry. Data represent mean ± SE of independent Western 





APAP-treated cells were harvested at several time points and the lysates were probed for 
JNK and P-JNK by Western blotting. APAP resulted in time-dependent JNK activation 
which was first detectable at 6 h, with progressive decrease subsequently (Fig. 2.4.4A). 
This result was confirmed by densitometry and the calculation of the P-JNK-to-JNK ratio 
(Fig. 2.4.4B). To determine whether activated JNK translocated into mitochondria as it 
does in mouse hepatocytes, cytosolic and mitochondrial fractions were isolated from 
PHH and JNK activation was evaluated at 6 and 15 h after APAP treatment. Similar to 
what was observed in total cell lysate, APAP exposure caused JNK activation in the 
cytosol at 6 and 15 h (Fig. 2.4.4C). Some JNK (mainly 54 kDa) was observed in 
mitochondria from controls, with a modest but significant increase in P-JNK 6 h after 
APAP exposure and massive P-JNK at 15 h (Fig. 2.4.4C). These results were confirmed 
by densitometry and the calculation of the P-JNK-to-JNK ratio (Fig. 2.4.4D). 
JNK inhibitor SP600125 partially protects against APAP-induced cell death in PHH 
Given the beneficial effect of the JNK inhibitor SP600125 in animals, we sought to 
determine whether it protects against APAP in PHH. Cells were treated with SP600125 
either simultaneously with APAP or 3 h after APAP, and cell death was evaluated at 24 
and 48 h. As SP600125 was dissolved in DMSO, a well-known inhibitor of cytochrome 
P450 enzymes, the concentration of SP600125 was limited to 10 μM to reduce 
interference with APAP metabolism. Despite this low concentration, SP600125 
consistently reduced cell death at both time points and with both treatment paradigms 
(Figs. 5A, B). To verify the ability of SP600125 to inhibit JNK activation in human 
hepatocytes, Western blotting was conducted. Treatment with this low concentration of 




Figure 2.4.5 JNK inhibitor SP600125 partially protects against APAP-induced cell 
death in PHH.  
JNK inhibitor SP600125 using 0.2% DMSO as the vehicle was administered either as (A) 
a cotreatment with APAP or (B) a 3-hour post-treatment after APAP. (C) Western 
blotting was performed to verify the efficacy of SP600125. Data represent mean ± SE 





cells without altering total JNK levels (Fig. 2.4.5C). Thus, JNK is involved in the 
progression of cell death after APAP in PHH. 
JNK is not relevant for APAP-induced cell death in HepaRG cells 
Previous data have demonstrated that HepaRG cells, a bipotent human hepatoma cell line, 
are a useful model to study APAP hepatotoxicity (McGill et al., 2011). For comparison, 
JNK activation in HepaRG cells was evaluated. Over a period of 24 h, JNK activation 
was barely detectable after APAP treatment, and total JNK levels remained almost 
constant (Fig. 2.4.6A). Surprisingly, co-treatment of SP600125 with APAP aggravated 
the injury rather than preventing it (Fig. 2.4.6B). Based on these data, JNK activation 
does not appear to be relevant for cell death after APAP in HepaRG cells. 
Protection against APAP-induced cell death in PHH by the clinical antidote N-
acetylcysteine 
To test if NAC is able to reduce APAP toxicity in PHH, cells were treated with 10 mM 
APAP and 20 mM NAC at the same time or 3-24 h after APAP. APAP alone caused 29% 
and 68% cell death at 24 and 48 h, respectively (Fig. 2.4.7A). NAC treatment completely 
prevented cell death at 24 h when given up to 6 h after APAP and significantly attenuated 
ALT release by 77% at 48 h (Fig. 2.4.7A). There was still a trend of reduced ALT release 
at 48 h when the cells were treated with NAC at 15 h. However, the protection by NAC 
was completely lost in the 24 h post-treatment group (Fig. 2.4.7A). When GDH as 
indicator for mitochondrial dysfunction was measured, NAC given either at the same 




exposure (Fig. 2.4.7B). Furthermore, NAC treatment eliminated JNK activation at 24 h 
(Figs. 2.4.7C, D).  
2.5 Discussion 
 
The aim of this investigation was to elucidate intracellular mechanisms of cell death after 
APAP in primary human hepatocytes. Importantly, we used freshly isolated cells. The 
hepatocytes were exposed to APAP immediately after isolation from fresh tissue and 
adherence to the tissue culture plates. Focusing on known events in murine hepatocytes, 
we observed similarities but also relevant differences between human and mouse cells 
which need to be considered when new therapeutic strategies are discussed. 
GSH depletion and protein adducts 
The electrophilic metabolite NAPQI reacts rapidly with GSH, causing extensive GSH 
depletion in mouse livers in vivo (> 80% within 30 min) (McGill et al., 2013) and in 
cultured mouse hepatocytes (> 80% within 3 h) (Bajt et al., 2004). Compared to the much 
more delayed GSH depletion in the metabolically competent human hepatoma cell line 
HepaRG (McGill et al., 2011), PHH responded very similar to mouse hepatocytes with a 
rapid GSH depletion of > 70% within 3 h. In addition, extensive protein adduct formation 
was observed in PHH with peak levels at 6 h. APAP protein adducts in mice and mouse 
hepatocytes peak around 2 h and 3 h, respectively (McGill et al., 2012b and McGill et al., 
2013). More importantly, protein adducts in mitochondria, which are thought to initiate 
mitochondrial dysfunction, also peak at the same time in mouse cells (McGill et al., 





Figure. 2.4.6 No JNK activation in HepaRG cells after APAP and no protection 
using JNK inhibitor SP600125.  
(A) Time course of JNK activation over 24 h in HepaRG cells. (B) Cell death as 
suggested by percentage of lactate dehydrogenase (LDH) released into the culture media 
at 24 h after APAP with or without JNK inhibitor SP600125 as a co-treatment. Data 
represent mean ± SE of n = 4. *P < 0.05 (compared with control), # P < 0.05 (compared 





Figure 2.4.7 Protection by N-acetylcysteine (NAC) against APAP-induced 
hepatotoxicity in PHH.  
20 mM NAC was applied at various time points after APAP and (A) ALT activity, (B) 
glutamate dehydrogenase (GDH) activity and (C–D) JNK activation was evaluated at 24 
h or 48 h after APAP. (D) Densitometry. Data represent mean ± SE from experiments 
using cells from 3 to 7 donors. *P < 0.05 (compared with control), # P < 0.05 (compared 




PHH compared to mouse hepatocytes and dramatically increased mainly after GSH 
depletion. Interestingly, on the basis of mg protein, APAP-Cys adducts levels were 1.5-
to-3-times higher in PHH than in mouse hepatocytes or livers in vivo. Thus, while GSH 
depletion and total protein binding in response to APAP is only minimally delayed 
compared to mouse hepatocytes, two fundamental differences between PHH and mice are 
the delayed mitochondrial protein adduct formation and the overall higher protein 
binding in human cells. A potential reason for the different time line in mitochondrial 
adduct formation could be an involvement of mitochondrial cyp2e1 in the process 
(Knockaert et al., 2011). However, further studies are required to investigate this 
hypothesis in detail. 
Mitochondrial dysfunction and JNK activation 
It is generally accepted that the early protein adduct formation in mouse hepatocytes 
leads to mitochondrial oxidant stress, which triggers the activation of several MAP 
kinases, including apoptosis signal-regulating kinase 1 (Nakagawa et al., 2008), mixed 
lineage kinase 3 (Sharma et al., 2012), receptor interacting protein kinases 1 and 3 
(Ramachandran et al., 2013 and Zhang et al., 2014), and glycogen synthase kinase-3 beta 
(Shinohara et al., 2010), all of which are thought to eventually trigger the downstream 
phosphorylation of JNK. P-JNK then translocates into mitochondria (Hanawa et al., 2008) 
and amplifies the mitochondrial oxidant stress (Saito et al., 2010a) to a level that can 
trigger MPT pore opening and cell necrosis (Kon et al., 2004). In PHH, JNK activation in 
the cytosol was delayed for several hours compared to mice, consistent with the delayed 
mitochondrial protein adduct formation. In addition, the mitochondrial translocation of P-




2008 and McGill et al., 2012b), was even more delayed in PHH. P-JNK translocation to 
mitochondria correlated with the collapse of the mitochondrial membrane potential 
followed by the onset of cell necrosis. Thus, many events observed in mouse hepatocytes 
in response to APAP also occur in PHH, but most of these events are substantially 
delayed and this may explain the delayed onset of necrosis in humans. 
The critical role of JNK activation as an amplification system in the pathophysiology of 
APAP hepatotoxicity has been demonstrated by the protection provided by the JNK 
inhibitor SP600125 or knock-down of JNK genes in vivo (Gunawan et al., 
2006 and Henderson et al., 2007). In contrast, the JNK inhibitor was only partially 
effective in cultured mouse hepatocytes, and only in the presence of the GSH synthesis 
inhibitor BSO (Gunawan et al., 2006). We have confirmed that the inhibitor was 
ineffective in protecting against APAP-induced cell death in cultured mouse hepatocytes 
(Y Xie and H Jaeschke, unpublished). Thus, the partial protection in PHH by SP600125 
suggests that JNK activation is an important step in the pathophysiology in humans. 
However, the concentration of the inhibitor used in our experiments was sub-optimal. A 
limitation of SP600125 is the need to use DMSO as solvent, which can prevent APAP-
induced hepatotoxicity due to inhibition of P450 enzymes even at very low 
concentrations and thus protect through off-target effects (Jaeschke et al., 2006). 
Interestingly, APAP did not cause JNK activation and SP600125 did not protect against 
APAP toxicity in HepaRG cells. Although we cannot rule out the possibility that 
hepatoma cells have altered signaling mechanisms, another explanation could be that 
other signaling pathways besides JNK are involved in the progression of injury. Recent 




both in vivo and in vitro (Saberi et al., 2014). However, a classical PKC inhibitor and 
knocking down of PKC-α protected through inhibition of JNK while broad-spectrum 
PKC inhibitors protected through a JNK-independent but AMPK-dependent pathway 
(Saberi et al., 2014). Preventing phosphorylation of AMPK by these PKC inhibitors led 
to activation of survival pathways such as autophagy (Saberi et al., 2014), which removes 
damaged mitochondria and protects against APAP-induced hepatotoxicity (Ni et al., 
2012a-b). Thus, the JNK pathway is an important amplification mechanism that 
aggravates the oxidant stress and promotes APAP-induced cell death in murine and 
human hepatocytes but PKC-mediated signaling independent of JNK may also contribute 
to the pathophysiology. 
Protection by the clinical antidote N-acetylcysteine in PHH 
For more than 35 years, NAC has been the only clinically approved antidote against 
APAP poisoning (Polson and Lee, 2005). NAC is most effective when given within 8 h 
of APAP overdose, but has been shown to be partially beneficial even when administered 
up to 24 h after APAP exposure (Smilkstein et al., 1988). The mechanism of protection 
during the early, metabolism phase primarily involves improved scavenging of the 
reactive metabolite NAPQI due to accelerated GSH synthesis (Corcoran et al., 1985), 
while the later effects include scavenging of mitochondrial oxidant stress and support of 
mitochondrial energy metabolism (Saito et al., 2010b). The experiments with delayed 
NAC treatment of PHH demonstrated complete protection up to 6 h after APAP, and 
partial protection when the cells were treated at 15 h. These results closely resemble the 
clinical effectiveness of NAC. In contrast, delayed NAC treatment in mice or mouse 




more accelerated pathophysiology in the murine systems. Thus, despite the usefulness of 
mice and mouse hepatocytes to study APAP-induced cell death, our results demonstrate 
that freshly isolated PHH are clearly superior to animal models and human cell lines. 
In summary, our results demonstrated rapid GSH depletion, formation of cellular and 
mitochondrial protein adducts, JNK activation and P-JNK translocation to mitochondria, 
loss of the mitochondrial membrane potential and cell necrosis in PHH after APAP 
exposure. Although the overall sequence of events was similar to mouse hepatocytes, 
there was clearly a substantial delay in formation of mitochondrial protein adducts, which 
occurred mainly after extensive GSH depletion. Similarly, JNK activation and 
translocation to the mitochondria were delayed. These events triggered the later loss of 
the mitochondrial membrane potential and cell necrosis. In addition, JNK inhibition was 
partially effective in PHH. Furthermore, NAC post-treatment was completely protective 
in PHH when administered as late as 6 h, and partially effective up to 15 h, after APAP. 
Overall, this timeline of APAP-induced cell death in PHH is very close to events 
observed in APAP overdose patients. Therefore, we can conclude that freshly isolated 
PHH are the best available model to study mechanisms of APAP-induced cell death and 
are the most relevant model for the human pathophysiology. Mouse hepatocytes or mice 
in vivo share many similarities with PHH, but differences in the time line of cell death 
and potentially in the details of signaling events are emerging. This means that it will be 
important to use PHH to test new therapeutic targets discovered in murine models before 










Chapter 3. N-acetyl-m-aminophenol (AMAP)-induced 

















This section is adapted from Xie et.al (2015), “Mitochondrial protein adducts formation 
and mitochondrial dysfunction during N-acetyl-m-aminophenol (AMAP)-induced 
hepatotoxicity in primary human hepatocytes”, Toxicology and Applied Pharmacology, 






3′-Hydroxyacetanilide or N-acetyl-meta-aminophenol (AMAP) is generally regarded as a 
non-hepatotoxic analog of acetaminophen (APAP). Previous studies demonstrated the 
absence of toxicity after AMAP in mice, hamsters, primary mouse hepatocytes and 
several cell lines. In contrast, experiments with liver slices suggested that it may be toxic 
to human hepatocytes; however, the mechanism of toxicity is unclear. To explore this, we 
treated primary human hepatocytes (PHH) with AMAP or APAP for up to 48 h and 
measured several parameters to assess metabolism and injury. Although less toxic than 
APAP, AMAP dose-dependently triggered cell death in PHH as indicated by alanine 
aminotransferase (ALT) release and propidium iodide (PI) staining. Similar to APAP, 
AMAP also significantly depleted glutathione (GSH) in PHH and caused mitochondrial 
damage as indicated by glutamate dehydrogenase (GDH) release and the JC-1 assay. 
However, unlike APAP, AMAP treatment did not cause relevant c-jun-N-terminal kinase 
(JNK) activation in the cytosol or phospho-JNK translocation to mitochondria. To 
compare, AMAP toxicity was assessed in primary mouse hepatocytes (PMH). No 
cytotoxicity was observed as indicated by the lack of lactate dehydrogenase release and 
no PI staining. Furthermore, there was no GSH depletion or mitochondrial dysfunction 
after AMAP treatment in PMH. Immunoblotting for arylated proteins suggested that 
AMAP treatment caused extensive mitochondrial protein adduct formation in PHH but 
not in PMH. In conclusion, AMAP is hepatotoxic in PHH and the mechanism involves 








APAP is a safe analgesic and antipyretic drug at therapeutic doses. However, APAP 
overdose can cause severe liver damage and even liver failure. Currently, it is the most 
prevalent cause of acute liver failure in the US and UK (Lee, 2012). Mechanistic 
investigations over the past several decades have revealed key events contributing to 
toxicity (Jaeschke et al., 2012 and Jaeschke et al., 2013). Bioactivation of APAP results 
in the formation of the toxic metabolite N-acetyl-p-benzoquinone imine (NAPQI). At 
therapeutic doses or mild overdoses, NAPQI can be detoxified by glutathione (GSH) with 
minimal protein binding ( McGill et al., 2013). However, after a more severe overdose, 
there is extensive hepatic GSH depletion and greater protein adduct formation (McGill et 
al., 2013). Interestingly, binding to mitochondrial proteins correlates with injury 
( Tirmenstein and Nelson, 1989 and McGill et al., 2012b). Mitochondrial protein binding 
precedes mitochondrial dysfunction (Meyers et al., 1988), mitochondrial oxidant stress 
( Jaeschke, 1990, Tirmenstein and Nelson, 1990 and Knight et al., 2001) (Knight et al., 
2001)and peroxynitrite formation (Cover et al., 2005). An initial oxidant stress activates 
and phosphorylates c-jun-N-terminal kinase (JNK), which then translocates to 
mitochondria ( Hanawa et al., 2008) where it amplifies the oxidative stress (Saito et al., 
2010a) and triggers opening of the mitochondrial permeability transition pore ( Kon et al., 
2004, Ramachandran et al., 2011a and LoGuidice and Boelsterli, 2011), resulting in cell 





3′-Hydroxyacetanilide or N-acetyl-meta-aminophenol (AMAP) is a regioisomer of 
APAP and also possesses analgesic and antipyretic properties (Baker et al., 1963). 
However, unlike APAP, studies in mice (Tirmenstein and Nelson, 1989), hamsters 
(Roberts et al., 1990), primary mouse hepatocytes (Holme et al., 1991) and TAMH cells 
(Pierce et al., 2002) have suggested that AMAP is not hepatotoxic. Several groups have 
proposed possible mechanisms to explain the discrepancy in toxicity, and most of the 
evidence suggests a critical role for mitochondria. It was demonstrated that, although 
AMAP and APAP caused similar total cellular protein binding, there was significantly 
less mitochondrial protein binding after AMAP ( Tirmenstein and Nelson, 1989 and 
Myers et al., 1995). Similarly, it was shown that the reactive metabolite of APAP 
extensively bound to mitochondrial proteins, while metabolites of AMAP preferentially 
bound to microsomal and cytosolic proteins ( Tirmenstein and Nelson, 1989, Streeter et 
al., 1984, Matthews et al., 1997 and Qiu et al., 2001). APAP also triggered robust 
nitrotyrosine protein adduct formation in mitochondria (Cover et al., 2005), while there 
was no appreciable mitochondrial protein nitration after AMAP (Abdelmegeed et al., 
2012). Consistent with those data, there is less cytosolic and mitochondrial GSH 
depletion after AMAP compared to APAP ( Nelson, 1980, Tirmenstein and Nelson, 1989, 
Rashed et al., 1990 and Hanawa et al., 2008). Furthermore, the lack of JNK activation 
and translocation to mitochondria in mice after AMAP suggested that AMAP did not 
particularly target mitochondria (Hanawa et al., 2008). Together these data indicated that 
mitochondrial dysfunction and mitochondrial protein binding are critical in determining 
toxicity. A widely accepted hypothesis to explain the difference in mitochondrial effects 




the site of formation in the endoplasmic reticulum (ER), leading to greater microsomal 
protein binding, while NAPQI can escape the ER and attack other organelles, including 
mitochondria (Rashed et al., 1990). 
 
A recent study revisited AMAP toxicity in precision-cut liver slices and found that 
AMAP was as toxic as APAP based on ATP depletion in rat and human liver slices (Hadi 
et al., 2013). However, the mechanism of AMAP toxicity in human liver cells was not 
investigated. These findings prompted us to evaluate the differences in the mechanisms 
of action between AMAP and APAP in PHH, and to compare across species. A better 













3.3 Materials and methods 
 
Isolation and treatment of primary human hepatocytes (PHH) 
All human tissues were acquired with informed consent from each patient according to 
ethical and institutional guidelines. The study was approved by the University of Kansas 
Medical Center Institutional Review Board. Table 3.4.1 provides a summary of medical 
information of donors. No donor tissue was obtained from executed prisoners or other 
institutionalized persons. All liver specimens were acquired in accordance with a Human 
Subject Committee approved protocol from patients undergoing a hepatic resection 
procedure or from donor livers. Hepatocytes were isolated as described in detail (Xie et 
al., 2014). Around 3 h after being seeded, cells were washed with sterile phosphate-
buffered saline (PBS) and treated with AMAP or APAP. Cells were harvested at different 
time points according to assays. 
Isolation and treatment of primary mouse hepatocytes (PMH) 
Primary hepatocytes were isolated as described in detail (Bajt et al., 2004). Cell viability 
of each isolation was generally more than 90%, and hepatocyte purity was > 95%. 
Following isolation, primary hepatocytes were plated with a concentration of 6 × 105 
cells per well and allowed 3 h to attach. The cells were then washed with PBS and 
exposed to AMAP or APAP. Cells were harvested at the indicated time points. 
Biochemical assays 
ALT activities were measured using an ALT reagent kit (Pointe Scientific, MI). LDH and 




modified Tietze assay was used to measure glutathione levels as described (Jaeschke and 
Mitchell, 1990). The JC-1 Mitochondrial Membrane Potential Kit (Cell Technology, 
Mountain View, CA) was used to measure the mitochondrial membrane potential as 
described in detail (Bajt et al., 2004). 
Propidium iodide (PI) staining 
PHH and PMH were treated with AMAP or APAP 3 h after seeding. The medium was 
removed after 48 h (PHH) or 15 h (PMH) and cells were stained with 500 nM of PI 
(Invitrogen) for 5 min. Nuclei were stained with 4′,6-diamidino-2-phenylindole (DAPI) 
and images were obtained with a fluorescence microscope. 
 
Isolation of subcellular fractions and Western blotting 
Mitochondria and cytosolic fractions were isolated using differential centrifugation as 
described (Xie et al., 2014). Western blotting was performed as described (Bajt et al., 
2000). A rabbit anti-JNK antibody and a rabbit anti-phospho-JNK antibody (Cell 
Signaling Technology, Danvers, MA) were used for JNK and phospho-JNK detection. A 
rabbit primary antibody was used to detect APAP or AMAP protein adducts. The 
antibody was raised against acetamidobenzoic acid and has been demonstrated to detect 
both APAP and AMAP protein adducts (Matthews et al., 1997 and Salminen et al., 1998). 
Statistics 
All results are expressed as mean ± standard error (SE). Comparisons between multiple 




Keul's test. If the data were not normally distributed, the Kruskal–Wallis Test was used 












Figure 3.4.1 AMAP induces cell death and GSH depletion in human hepatocytes. 
 Primary human hepatocytes (PHH) were treated with 10 mM of AMAP or APAP over a 
period of 48 h, and the percentage of alanine aminotransferase (ALT) release was 
measured at 24 h (A) and 48 h (B) to evaluate toxicity. (C) Dose–response of AMAP 
toxicity at 48 h after treatment. (D) Glutathione depletion after 10 mM AMAP or APAP 
exposure for 24 h. Data represent mean ± SE from experiments using cells from 3 to 10 





3. 4 Results 
 
AMAP induces cell death and GSH depletion in primary human hepatocytes 
Freshly isolated primary human hepatocytes (PHH) were treated with 10 mM AMAP or 
APAP for 48 h. APAP triggered significant cell death as indicated by the percentage of 
alanine aminot after treatment (Fig. 3.4.1A,B). AMAP did not cause significant 
cytotoxicity until 48 h (Fig. 3.4.1B). Consistent with that, toxicities of both AMAP and 
APAP at 48 h were confirmed by the cellular uptake of red fluorescent PI stain (Fig. 
3.4.2). PI cannot enter live cells but upon membrane permeabilization during necrosis, 
the stain enters the cells and binds to nuclear DNA, which enhances the red fluorescence. 
An overlay of PI with the nuclear stain DAPI or the phase contrast images confirms the 
nuclear localization of the PI staining indicative of necrotic cell death in PHH after 
exposure to APAP and AMAP (Fig. 3.4.2). At both 24 h and 48 h, AMAP was less toxic 
than APAP (Fig. 3.4.1A, B). The hepatotoxicity of AMAP was dose-dependent (Fig. 
3.4.1C). Exposure to 10 mM AMAP triggered substantial GSH depletion at 24 h, 
although this effect was less dramatic than after APAP (Fig. 3.4.1D). Overall, although 
AMAP has a reduced propensity to cause necrotic cell death compared to APAP, our data 
clearly show that it is toxic in PHH. 
AMAP triggers mitochondrial dysfunction in PHH without JNK activation or P-
JNK translocation to mitochondria 
Given the importance of mitochondria in the toxicity after APAP in mice and humans, we 
hypothesized that AMAP caused mitochondrial dysfunction in PHH. To test this 




mitochondrial matrix that is released into the serum upon mitochondrial damage (McGill 
et al., 2012a), was evaluated. Significant release of GDH was observed in both AMAP- 
and APAP-treated hepatocytes at 48 h after treatment, and the effect of AMAP was dose-
dependent (Fig. 3.4.3A,B). Consistent with that, the JC-1 assay revealed the significant 
loss of mitochondrial membrane potential after AMAP by a decline of the red-to-green 
fluorescence ratio, although the decrease was less extensive than after exposure to APAP 
(Fig. 3.4.3C). Importantly, compared with APAP, the less severe mitochondrial 
dysfunction after AMAP correlated with the lower ALT release and GSH depletion after 
AMAP compared to APAP (Fig. 3.4.1). JNK activation and translocation, which are 
critical amplifying events in APAP-induced hepatotoxicity, were also assessed after 
AMAP treatment (Fig. 3.4.4). At 6 and 24 h after AMAP exposure, an increase in total 
JNK compared to untreated cells was observed in the cytosol, which was paralleled by a 
modest increased expression of P-JNK (Fig. 3.4.4A). However, the ratio of P-JNK-to-
total JNK did not change significantly before or after AMAP (Fig. 3.4.4C). Furthermore, 
there was no P-JNK translocation to mitochondria and only a minor JNK translocation at 
24 h (Fig. 3.4.4B). Compared to APAP, JNK activation and P-JNK translocation to the 
mitochondria after AMAP is negligible (Fig. 3.4.4B). Taken together, AMAP causes 
significant mitochondrial dysfunction, but JNK activation and phospho-JNK 




Figure. 3.4.2 AMAP and APAP induce necrosis in human hepatocytes.  
Primary human hepatocytes (PHH) were treated with 10 mM of AMAP or APAP over a 
period of 48 h and necrotic cell death as indicated by nuclear PI staining was assessed. 
DAPI, 4′,6-Diamidino-2-Phenylindole (nuclear stain); PI, propidium iodide (nuclear stain 




Figure 3.4.3 AMAP triggers mitochondrial dysfunction in PHH. 
 (A) Percentage of glutamate dehydrogenase (GDH) release into the culture medium at 48 
h after 10 mM AMAP or APAP. (B) Dose– response of GDH release at 48 h after AMAP 
(5–20 mM). (C) Loss of mitochondria membrane potential after 24 h exposure to 10 mM 
AMAP or APAP as indicated by the decrease of the red/ green fluorescence ratio using 
the JC-1 assay. Data represent mean ± SE from experiments using cells from 8 donors. 





Figure 3.4.4 No JNK activation or mitochondrial translocation after AMAP in PHH. 
 JNK activation in the cytosol (A) and P-JNK translocation to the mitochondria (B) were 
evaluated by Western blotting. Mitochondrial fraction from APAP-treated PHH was used 
as positive control. (C) Densitometry of cytosolic JNK activation. Data represent mean ± 




Figure 3.4.5 No significant mitochondrial dysfunction or cell death after AMAP in 
primary mouse hepatocytes (PMH).  
(A) Lactate dehydrogenase was measured as an indicator of cell death after exposure to 
5–20 mM AMAP or 5 mM APAP for 15 h. (B) GSH depletion at 5 h after 5 mM AMAP 
or APAP. Loss of mitochondrial membrane potential at 5 h (C) and 16 h (D) after AMAP 
and APAP were assessed by decrease of red/green fluorescence ratio using the JC-1assay. 
Data represent mean ± SE from experiments using primary mouse hepatocytes from 4 
different isolations. *P < 0.05 (compared with controls); # P < 0.05 (compared with the 




Figure 3.4.6 APAP but not AMAP caused cell necrosis in mouse hepatocytes.  
Primary mouse hepatocytes (PMH) were treated with 5 mM of AMAP or APAP over a 
period of 15 h and necrotic cell death as indicated by nuclear PI staining was assessed. 
DAPI, 4′,6-Diamidino-2-Phenylindole (nuclear stain); PI, propidium iodide (nuclear stain 





No injury or significant mitochondrial dysfunction after AMAP in primary mouse 
hepatocytes (PMH) under the conditions studied 
For comparison, primary mouse hepatocytes were treated with 5 mM APAP or various 
concentrations of AMAP. Consistent with previous findings, AMAP was not significantly 
toxic even at 20 mM as demonstrated by the lack of lactate dehydrogenase (LDH) release. 
However, 5 mM APAP resulted in extensive cell death (80% release of total LDH into 
culture medium) (Fig. 3.4.5A). The necrotic cell death after APAP was confirmed by 
cellular uptake of the red PI stain using immunofluorescent staining (Fig. 3.4.6). 
Consistent with the lack of LDH release, AMAP-treated cells did not show any cellular 
PI uptake. Overlay of PI with the nuclear stain DAPI or phase contrast images confirmed 
the nuclear localization of the PI stain in APAP but not AMAP-treated cells (Fig. 3.4.6). 
A similar trend was observed with GSH content, as exposure of AMAP had no 
significant effect on GSH levels while APAP caused 92% depletion of total GSH (Fig. 
3.4.5B). In contrast to PHH, no mitochondrial dysfunction was observed in PMH at either 
5 h or 16 h after AMAP (Fig. 3.4.5C, D). Based on these data we conclude that AMAP 
does not induce cell death or mitochondrial dysfunction in PMH under the conditions 
studied. 
AMAP induces a significant increase of mitochondrial protein binding in PHH but 
not in PMH under the conditions studied 
As mitochondrial protein binding is thought to be a key event in the initiation of APAP 
toxicity in mice, covalent binding in mitochondria from PHH was measured by 




used that can detect both APAP and AMAP protein adducts (Matthews et al., 
1997 and Salminen et al., 1998). In PHH, extensive mitochondrial protein adducts 
formation was detected at 6 and 24 h after AMAP exposure (Fig. 3.4.7A,B). Note that the 
adduct bands consist of various proteins with molecular weights ranging from 30 to 
250 kDa. A comparison to adduct detection in AMAP-treated PMH clearly indicates 
lower overall mitochondrial protein adducts formation in PMH than in PHH (Fig. 
3.4.7A,B,C). On the other hand, a substantial number of mitochondrial protein adducts 
were observed in PMH after APAP treatment (Fig. 3.4.7A). The unexpected bands in the 
SDS control lane (Fig. 3.4.7A) were caused by SDS as this band was absent when only 
buffer was used (Supplemental Figure). Thus, despite less protein loading on the gel (as 
seen by the lower porin detection), APAP appeared to trigger much higher mitochondrial 
protein adducts formation than AMAP in PMH. Nevertheless, these data suggest that 
AMAP exposure results in significantly more mitochondrial covalent protein binding in 
PHH, which may be involved in AMAP-induced mitochondrial damage and 




The aim of this study was to investigate the mechanisms of AMAP hepatotoxicity in 
freshly isolated PHH and PMH. In contrast to results in mice and PMH, we found that 
AMAP is toxic to PHH. Comparison between PHH and PMH suggested the importance 





Figure 3.4.7 AMAP induces covalent protein binding in PHH but not PMH. 
 (A) Mitochondrial fractions were isolated from PHH and PMH which were treated with 
AMAP for 6 h or 24 h. Mitochondrial fraction from APAP-treated PMH was used as a 
positive control, and a blank (bl) lane loaded with only SDS loading buffer was used as a 
negative control. 0 h lanes represent mitochondria samples of control PHH or control 
PMH without any treatment. Porin was used as a loading control. (B) (C) Densitometry 
of adduct levels normalized to porin for PHH and PMH. The results of each 0 h lane were 
set to 1 and the data for AMAP-treated cells are expressed as fold increase over baseline. 
Data represent mean ± SE from experiments using primary human or mouse hepatocytes 





Figure 3.4.7 AMAP induces covalent protein binding in PHH but not PMH. (A) 
Mitochondrial fractions were isolated from PHH and PMH which were treated with 
AMAP for 6 h or 24 h. Mitochondrial fraction from APAP-treated PMH was used as a 
positive control, and a blank (bl) lane loaded with only SDS loading buffer was used as a 
negative control. 0 h lanes represent mitochondria samples of control PHH or control 
PMH without any treatment. Porin was used as a loading control. (B) (C) Densitometry 
of adduct levels normalized to porin for PHH and PMH. The results of each 0 h lane were 
set to 1 and the data for AMAP-treated cells are expressed as fold increase over baseline. 
Data represent mean ± SE from experiments using primary human or mouse hepatocytes 





Supplemental Figure SDS buffer results in non-specific binding during western 
blotting.  
To assess the cause of the non-specific bands observed in the SDS lane in Figure 7A, the 
western blot was repeated and SDS buffer was compared with SDS-free buffer.  A 
mitochondrial fraction from primary mouse hepatocytes (PMH) treated with APAP for 6 






Mitochondrial protein adducts formation in AMAP-induced hepatotoxicity 
AMAP has long been considered a non-hepatotoxic analog of APAP. The main reason 
for the difference in toxicity in mice appears to be protein adducts formation. When 
directly compared to APAP, AMAP triggers comparable total protein adducts formation 
but induces significantly less mitochondrial adducts (Myers et al., 1995, Tirmenstein and 
Nelson, 1989 and Qiu et al., 2001). Therefore, it was concluded that mitochondrial 
protein adduct levels, rather than total cellular adduct levels, correlate with toxicity. The 
more recent data showing that AMAP can cause toxicity (ATP depletion) in human liver 
slices cast some doubt on this conclusion (Hadi et al., 2013). However, our data suggest 
that mitochondrial protein binding in fact correlates with toxicity in PHH, and the 
significant disparity in mitochondrial adduct levels readily explains the species difference 
in our study. Currently two approaches are commonly used for assessment of protein 
adducts formation after AMAP: detection of radiolabeled adducts and detection with 
antibodies. A comparison of the two methods indicate similar performance of adduct 
detection after AMAP either quantitatively or qualitatively. Importantly, both approaches 
suggest low levels of mitochondrial adducts in PMH (Myers et al., 1995). As antibody 
detection performs equally as well as radiolabeling, which is generally the gold standard 
method to detect protein adducts, the limited detection of mitochondrial protein adducts 
observed here in PMH after AMAP is most likely due to actually low levels of adducts. 
Admittedly, we cannot guarantee that this antibody is able to detect all mitochondrial 
adducts in mouse samples. However, since the antibody appears to detect large numbers 
of mitochondrial AMAP adducts in PHH, one would have to assume a dramatically 




appears unlikely. Nevertheless, alternative detection methods are necessary for further 
verification. 
Although the mitochondrial adducts profile in PHH after AMAP treatment appears to be 
similar to that in PMH after APAP (Fig. 2.4.7), a more detailed analysis of the adducted 
proteins is needed to determine if similar proteins were adducted. Proteomic investigation 
in mice demonstrated that proteins modified by AMAP constitute a subgroup of proteins 
modified by APAP in that species (Fountoulakis et al., 2000). Other studies narrowed 
down the list of adducted proteins and indicated that microsomal proteins, especially 
Cyp2e1, are the main targets of AMAP (Myers et al., 1995, Matthews et al., 
1997 and Halmes et al., 1998) (Halmes et al., 1998). However, that is beyond the scope 
of the current study. The fact that there appear to be more mitochondrial protein adducts 
after APAP correlates with the more severe mitochondrial dysfunction and higher cell 
death after APAP compared to AMAP under the conditions studied. In addition, previous 
data from a comparison of APAP toxicity in rats and mice suggest that the extent of 
mitochondrial protein binding correlates with liver injury (McGill et al., 2012b). 
Collectively, our data together with previous findings consistently support the idea that 
mitochondrial protein adduct levels correlate with hepatotoxicity. 
Mitochondrial dysfunction in AMAP-induced hepatotoxicity 
The critical role of mitochondria in APAP-induced hepatotoxicity has been well 
established (Jaeschke et al., 2012 and Jaeschke et al., 2013). Specifically, mitochondria 
are involved in APAP toxicity by covalent protein binding (Tirmenstein and Nelson, 




peroxynitrite formation (Cover et al., 2005), JNK activation and P-JNK translocation to 
mitochondria (Hanawa et al., 2008), oxidant stress amplification (Saito et al., 2010a), 
mitochondrial Bax pore formation (Bajt et al., 2008), the mitochondrial membrane 
permeability transition pore opening (Kon et al., 2004) and mitochondrial endonuclease 
translocation to the nucleus (Bajt et al., 2006). Similar mechanisms were observed in the 
metabolically competent human hepatoma cell line HepaRG (McGill et al., 2011) and in 
primary human hepatocytes (Xie et al., 2014). For AMAP, previous reports have shown a 
limited relevance of mitochondria. AMAP leads to microsomal protein binding rather 
than the mitochondrial protein binding observed after APAP (Tirmenstein and Nelson, 
1989 and Rashed et al., 1990; Myers et.al., 1995). Compared with APAP, AMAP 
depletes total GSH and mitochondrial GSH to a lesser extent   (Nelson 1980)(Nelson, 
1980, Tirmenstein and Nelson, 1989, Rashed et al., 1990 and Hanawa et al., 2008), 
despite the fact that a number of glutathione conjugates were identified in vitro (Rashed 
and Nelson, 1989). In contrast to APAP, AMAP did not disrupt mitochondrial calcium 
homeostasis by impairing the capacity to sequester calcium (Tirmenstein and Nelson, 
1989). Thus, consistent evidence in mice indicates that AMAP does not appear to target 
mitochondria in that species. However, pharmacological intervention using BSO to 
deplete mitochondrial GSH made mice more vulnerable to AMAP (Tirmenstein and 
Nelson, 1991). Under these conditions, there was more mitochondrial protein binding 
correlating with AMAP toxicity in mice (Tirmenstein and Nelson, 1991). Overall, this led 
to the hypothesis that metabolites of AMAP may be too reactive to reach mitochondria 
under physiological conditions in mice (Rashed et al., 1990 and Myers et al., 1995). Our 




as a result of mitochondrial protein binding in PHH and the resulting mitochondrial 
damage likely led to cell death. This suggests more of a species difference in AMAP 
toxicity rather than a totally different mechanism. In support of this hypothesis, we have 
previously shown that the species difference in the time course of APAP toxicity between 
mice and humans is caused by the much more delayed protein adducts formation, 
especially in mitochondria, leading to delayed oxidant stress and JNK activation (Xie et 
al., 2014). In addition, the apparently nontoxic APAP analog, 2,6-dimethyl APAP, (2,6-
DMA) was cytotoxic in PMH from phenobarbital-pretreated mice (Birge et al., 1989). 
Although the authors did not specifically assess mitochondrial protein adducts, the 
cytotoxicity of 2,6-DMA in PMH correlated with enhanced protein binding (Birge et al., 
1989). These examples suggest that the cytotoxicity of AMAP or 2,6-DMA in PMH is 
mainly dependent on the experimental conditions. However, whether these difference in 
AMAP toxicity is only caused by a different metabolite profile and spectrum of adducts 
formed in human compared to mouse cells or if there are other factors involved remains 
to be investigated. 
The metabolism profile of AMAP is different between mice and humans. In mice, around 
40% of AMAP is eliminated either unaltered or conjugated with glucuronic acid or 
sulfate (Rashed et al., 1990). The remaining AMAP is metabolized by P450 enzymes to 3 
major proximate metabolites which are 2,5-diOH-acetanilide, 3-OH-APAP and 3-OMe-
APAP. These hydroquinones can be conjugated with glucuronic acid or sulfate, or they 
could be further converted to reactive quinones, which bind to GSH or attack cellular 
proteins (Kenna 2013). In precision-cut liver slices, it was reported that sulfation is the 




human liver slices (Hadi et al., 2013). Besides, levels of three hydroquinones, which are 
precursors of the toxic quinones differ significantly in mice and humans (Hadi et al., 
2013). It is also possible that different cytochrome P450s are involved in AMAP 
metabolism in different models. Future investigations regarding the species differences 
are necessary to elucidate the different mechanisms of actions. 
JNK activation and AMAP-induced hepatotoxicity 
Interestingly, no P-JNK translocation to the mitochondria was observed in PHH after 
AMAP treatment. After APAP overdose, JNK activation and mitochondrial P-JNK 
translocation are critical for the mechanism of liver injury in mice (Hanawa et al., 2008). 
In addition, knock-down or inhibition of many kinases, including apoptosis signal-
regulating kinase 1 (Nakagawa et al., 2008 and Xie et al., 2015c), mixed-lineage kinase 3 
(Sharma et al., 2012) and glycogen synthase kinase-3beta (Shinohara et al., 2010) has 
revealed that they are involved in activation of JNK and translocation of P-JNK to 
mitochondria, which are critical amplifying events for the initial oxidative stress. For 
AMAP, previous studies demonstrated the absence of JNK activation in other models 
after AMAP treatment. In TGF-alpha transgenic mouse hepatocytes (TAMH), which 
exhibited susceptibility to APAP and resistance to AMAP, AMAP induced less JNK and 
c-Jun activation compared to APAP (Stamper et al., 2010). In fact, JNK siRNA had no 
effect on cell death after AMAP while it was able to attenuate the cytotoxicity after 
APAP (Stamper et al., 2010). Similarly, in mice there is no JNK activation or 
mitochondrial translocation after AMAP (Hanawa et al., 2008). However, there was no 
toxicity after AMAP in these models. In contrast, our data indicate AMAP hepatotoxicity 




suggesting cell death in the absence of JNK activation. Interestingly, even in APAP-
induced liver injury, JNK activation is not always necessary for the cell death 
mechanisms. In HepaRG cells, APAP triggers mitochondrial dysfunction and cell death 
without JNK activation (McGill et al., 2011 and Xie et al., 2014). In PHH hepatocytes, 
APAP causes JNK activation but JNK inhibitors are only moderately protective (Xie et 
al., 2014). Similarly, PKC inhibitors attenuate APAP-induced liver injury in mice by 
preventing phosphorylation of AMPK and by activating autophagy in a JNK-independent 
way (Saberi et al., 2014). Together these data suggest that although JNK is important for 
most models of APAP hepatotoxicity, especially in mice, it does not contribute to cell 
death after AMAP in PHH. 
In summary, our results demonstrated the hepatotoxicity of AMAP in PHH. The cell 
death was preceded by GSH depletion and loss of mitochondrial membrane potential. 
JNK activation was likely not involved in AMAP toxicity. In contrast, no GSH depletion, 
mitochondrial dysfunction or cell death was observed in PMH after AMAP. Comparison 
between PHH and PMH revealed that AMAP induces a significant increase of 
mitochondrial protein binding in PHH but not in PMH under the conditions studied. Our 
data emphasize the importance of mitochondrial dysfunction and sustained mitochondrial 
protein binding in determining hepatotoxicity in human hepatocytes after AMAP 
treatment, and also indicate that species differences in protein adduct formation should be 









Chapter 4. Lack of Direct Cytotoxicity of Extracellular ATP 



















This section is adapted from Xie et.al (2015), “Lack of direct cytotoxicity of extracellular 
ATP against hepatocytes: role in the mechanism of acetaminophen hepatotoxicity”, 







Background: Acetaminophen (APAP) hepatotoxicity is a major cause of acute liver 
failure in many countries. Mechanistic studies in mice and humans have implicated 
formation of a reactive metabolite, mitochondrial dysfunction and oxidant stress as 
critical events in the pathophysiology of APAP-induced liver cell death. It was recently 
suggested that ATP released from necrotic cells can directly cause cell death in mouse 
hepatocytes and in a hepatoma cell line (HepG2).  
Aim: To assess if ATP can directly cause cell toxicity in hepatocytes and evaluate their 
relevance in the human system. Methods: Primary mouse hepatocytes, human HepG2 
cells, the metabolically competent human HepaRG cell line and freshly isolated primary 
human hepatocytes were exposed to 10-100 µM ATP or ATγPin the presence or absence 
of 5-10 mM APAP for 9-24 h.  
Results: ATP or ATγP was unable to directly cause cell toxicity in all 4 types of 
hepatocytes. In addition, ATP did not enhance APAP-induced cell death observed in 
primary mouse or human hepatocytes, or in HepaRG cells as measured by LDH release 
and by propidium iodide staining in primary mouse hepatocytes. Furthermore, addition of 
ATP did not cause mitochondrial dysfunction or enhance APAP-induced mitochondrial 
dysfunction in primary murine hepatocytes, although ATP did cause cell death in murine 
RAW macrophages.  
Conclusions: It is unlikely that ATP released from necrotic cells can significantly affect 
cell death in human or mouse liver during APAP hepatotoxicity. Relevance for patients: 









Acetaminophen, a safe analgesic drug at therapeutic doses, can induce severe liver injury 
and even liver failure after overdose in experimental animals and in humans (Larson, 
2007, McGill et al., 2012a). Although the focus of pathophysiological studies during the 
last four decades was on intracellular signaling mechanisms (Nelson, 1990; Cohen et al., 
1997; Jaeschke et al., 2012a), in recent years a contribution of the innate immune 
response has been discussed (Jaeschke et al., 2012b). A sterile inflammatory response is 
activated by release of damage-associated molecular patterns (DAMPs) such as nuclear 
DNA fragments, mitochondrial DNA, high mobility group box protein 1 protein 
(HMGB1) and ATP from necrotic hepatocytes (McGill et al., 2012a; Martin-Murphy et 
al., 2010; Antoine et al., 2012). The activation of toll-like receptors on macrophages by 
DAMPs leads to the transcriptional activation of pro-inflammatory cytokines including 
pro-IL-1β. In addition, stimulation of purinergic receptors by ATP activates the Nalp3 
inflammasome, triggering the activation of caspase-1 which processes the pro-IL-1β to 
the active cytokine (Hoque et al., 2012). Although we could not confirm a role of 
caspase-1, the Nalp3 inflammasome and IL-1β (Williams et al., 2010b, 2011), or the 
purinergic receptor P2X7 (Xie et al., 2013) during APAP hepatotoxicity, a recent paper 
introduced a novel hypothesis for the role of ATP released by necrotic cells. Amaral et al 
(2013) provided evidence that human hepatoma cells (HepG2) exposed to APAP release 




primary mouse hepatocytes and HepG2 cells can be directly killed by exposure to ATP at 
concentrations between 10 and 100 µM (Amaral et al., 2013). Thus, in addition to 
activating the inflammasome, ATP may directly contribute to aggravation of APAP-
induced liver injury as a cytotoxic agent (Amaral et al., 2013). This novel concept would 
support a previous hypothesis that “death factors” released by necrotic cells are involved 
in the expansion of the original injury (Mehendale, 2012). If this hypothesis can be 
supported, any ATP leaking out of necrotic cells could be potentially dangerous for 
neighboring cells. This novel hypothesis could have a substantial impact not only on the 
mechanism of APAP hepatotoxicity but also on a large number of other liver disease 
models, e.g. ischemia-reperfusion injury, where extensive necrosis occurs (Jaeschke, 
2003). Therefore, the objective of the current study was to determine if ATP is directly 
cytotoxic in 4 different cell culture models: primary cultured mouse and human 
hepatocytes and a metabolically competent (HepaRG) and a metabolically deficient 
(HepG2) hepatoma cell line. Alternatively, it was hypothesized that ATP could aggravate 










4.3 Materials and Methods 
 
HepaRG and HepG2 cell lines 
HepaRG cells were acquired from Biopredic International (Rennes, France).The detailed 
process of HepaRG cell culture was described previously (McGill et al., 2011). HepG2 
cells obtained from ATCC (Manassas, VA, USA) were cultured in DMSO (dimethyl 
sulfoxide)-free Williams’ E medium containing penicillin/streptomycin, insulin and 10% 
fetal bovine serum, and were 70%~80% confluent before treatment. Both cell lines were 
treated with 10 mM APAP (Sigma, St. Louis, MO, USA) dissolved in warm Williams’ E 
medium. ATP (Sigma) was dissolved in saline and added to the cell culture medium to a 
final concentration of 10 µM or 100 µM. Twenty-four hours after treatment of either 
ATP and/or APAP, medium and cell fractions were harvested, and cell viability was 
determined using the lactate dehydrogenase (LDH) assay (Bajt et al., 2004).  
Primary mouse hepatocytes  
Primary mouse hepatocytes were isolated by a two-step isolation procedure as previously 
described in detail (Bajt, et.al, 2004). The animals used were 8 week old male C57Bl/6 
mice (Jackson Laboratories, Bar Habor, Maine, USA). Animals were acclimatized for at 
least 3 days and fasted overnight before cell isolation. All experimental protocols were 
approved by the Institutional Animal Care and Use Committee of the University of 
Kansas Medical Center.  Generally, cell viability of each isolation was more than 90%, 
and cell purity was >95% hepatocytes. Cells were treated with 5 mM APAP, which was 
dissolved in warm Williams’ E medium. ATP was dissolved in saline and added to the 




cells and supernatants were harvested 9 h or 24 h after the treatment. The LDH assay was 
carried out to assess the cell death. 
Primary human hepatocytes 
Freshly isolated primary human hepatocytes were obtained from the Biospecimen Core in 
the Department of Pharmacology, Toxicology and Therapeutics at The University of 
Kansas Medical Center. The liver sources were either unused tissue from donor livers or 
material from liver resections. All human tissues were obtained with informed consent 
according to ethical and institutional guidelines. Hepatocytes were isolated as previously 
described (Gramignoli et. al, 2012) using a 3 step process and the dissociation enzymes 
collagenase (Vitacyte, Indianapolis, Indiana, USA) and protease (Vitacyte). Human 
hepatocytes were plated in Hepatocyte Maintenance Medium (HMM, Lonza Group, 
Basel, Switzerland) supplemented with dexamethasone, insulin and 
gentamicin/amphotericin-B (Lonza) and 5% newborn calf serum (Atlanta Biologicals, 
Lawrenceville, Georgia, USA) was used to maintain the hepatocytes. The hepatocytes 
were allowed to attach for 2 hours in a 37°C, 5% CO2 incubator before treatment. Cells 
were treated with 10 mM APAP dissolved in warm HMM, and all cells were harvested at 
24 h post-treatment. For ATP treatment, ATP was dissolved in saline and added to the 
cell culture medium to a final concentration of 10 µM or 100 µM. After cell harvesting, 
alanine aminotransferase (ALT) activities were measured in cells and the supernatant 






All results were expressed as mean  SE. Comparisons between multiple groups were 
performed with one-way ANOVA followed by a post hoc Bonferroni test. If the data 
were not normally distributed, we used the Kruskal-Wallis Test (nonparametric ANOVA) 







Primary mouse hepatocytes  
Previous results showed that cultured hepatocytes release ATP into the supernatant after 
exposure to 20 mM APAP resulting in concentrations of up to 10 µM (Amaral et al., 
2013). Therefore, primary mouse hepatocytes were exposed to 10 or 100 µM ATP in the 
presence or absence of 5 mM APAP for 9 h (Figure 1). 
Based on LDH release as indicator for cell necrosis (Bajt et al., 2004), ATP alone did not 
cause more cell death compared to untreated mouse hepatocytes. In addition, ATP did not 
trigger additional necrosis in cells exposed to APAP (Figure 1A). Similar results were 
obtained when JC-1 fluorescence was measured as indicator of the mitochondrial 
membrane potential (Figure 1B). ATP alone did not cause mitochondrial dysfunction and 
ATP did not aggravate APAP-induced loss of the mitochondrial membrane potential 
(Figure 1B). These results were similar to experiments with ATP concentrations of up to 
10 mM and longer time points (24 h) (data not shown). To confirm these results, 
propidium iodide staining was performed to assess the number of necrotic cells (Figure 2). 
No differences were observed between the ATP and control groups or the APAP and 
APAP + ATP groups; the overall cell death was consistent with previous results. Finally, 
a non-hydrolyzable form of ATP (ATγP) was used in place of ATP as described by 
Amaral et al. (2013) and LDH was measured to assess cell death (Figure 3). The use of 
the ATγP yielded the same results, as no increase in cell death was found with ATγP 
alone or with co-treatment of ATγP and APAP (Figure 3).  




Figure 4.4.1 Effect of ATP on primary mouse hepatocytes.  
Primary mouse hepatocytes were treated with 5 mM acetaminophen dissolved in 
Williams’ E medium, and cell death was assessed by the percentage of lactate 
dehydrogenase (LDH) released into the medium from the cells at 9 h after the treatment 
(A). ATP was freshly dissolved in saline and added to the cell culture medium to a final 
concentration of 10 µM or 100 µM at the time of APAP treatment. JC-1 fluorescence was 
measured to assess mitochondrial dysfunction (B). Data represent mean ± SE of n=4 






Figure 4.4.2 ATP does not increase cell death in murine hepatocytes exposed to 
APAP.  
Primary mouse hepatocytes were treated with ATP in the presence or absence of 5 mM 
acetaminophen and cell death was assessed by propidium iodide/DAPI staining (A). 
Quantification was done by counting PI-positive cells in four different fields per well 
from different cell isolations. Data represent mean ± SE of n = 3 different mouse 





Figure 4.4.3 Non-hydrolyzable ATP (ATγP) does not increase cell death in 
hepatocytes.  
Primary mouse hepatocytes were treated with 10 µM or 100 µM ATγP in the presence or 
absence of 5 mM acetaminophen and cell death was assessed by LDH release. Data 
represent mean ± SE of n = 3 different mouse hepatocytes isolations *p<0.05 (compared 





Using freshly isolated primary human hepatocytes, a moderate degree of necrosis (ALT 
release) was observed after exposure to 10 mM APAP for 24 h as compared to untreated 
cells (controls) (Figure 4A). Similar to primary mouse hepatocytes, exposure to ATP did 
not cause any additional cell death in human hepatocytes compared to untreated cells or 
compared to APAP-treated cells (Figure 4A). The same results were obtained in the 
metabolically competent HepaRG cell line cultured with the same concentrations of 
APAP and ATP; again ATP failed to increase cell death in any treatment (Figure 4B). 
Because previous studies showed evidence of ATP cytotoxicity in HepG2 cells (Amaral 
et al., 2013), HepG2 cells were exposed to ATP in the presence or absence of 10 mM 
APAP. Similar to our previous findings (McGill et al., 2011), APAP did not cause cell 
death in HepG2 cells (Figure 4C). More importantly, neither 10 nor 100 µM ATP caused 
cell death in control HepG2 cells or in cells exposed to APAP (Figure 4C).  
Cytotoxicity of ATP in the macrophage cell line RAW264.7  
We measured ATP based-cytotoxicity in a macrophage cell line that expressed purinergic 
receptors (Kawano et al., 2012).Stimulating macrophages with ATP at concentrations up 
to 200 µM produced no toxicity with an incubation time of 9 h; however, longer 
incubation times (72 h) produced significant toxicity at a concentration of 200 µM 
(Figure 5). While these concentrations are extremely high and certainly well beyond even 
pathophysiological concentrations, these data do indicate that ATP is both stable and 
active in vitro, and can produce toxicity given long incubation times and higher 
concentrations. These data are supported by previous studies on the biological activity 






Figure 4.4.4 ATP does not increase cell death in human hepatocytes or hepatoma 
cell lines.  
Primary human hepatocytes (A), HepaRG cells (B) or HepG2 cells were treated with 
ATP in the presence or absence of 5 mM acetaminophen and cell death was assessed by 
ALT or LDH release. Data represent mean ± SE of n=3 different HepaRG cell 
differentiations, n=3 HepG2 cell preparations and n=8 human hepatocyte isolations. * 







Figure 4.4.5 Cytotoxicity of ATP in RAW 264.7 macrophages.  
RAW macrophages were exposed to increasing concentrations of ATP for 9 or 72 h, 
respectively, and then cell viability was measured via the SRB test. Data represent mean 





4.5 Discussion  
 
The objective of this investigation was to determine if ATP can act as a direct cytotoxic 
agent against hepatocytes or can aggravate APAP-induced cell death. This hypothesis 
was tested in 4 different types of hepatocytes, i.e., primary mouse hepatocytes, primary 
human hepatocytes, a metabolically competent human hepatoma cell line (HepaRG) and 
a human hepatoma cell line that does not express CYPs or other drug metabolizing 
enzymes (HepG2). Consistent in all 4 cell types, various doses of ATP were unable to 
directly cause cell death and were also not able to enhance APAP-induced cell necrosis; 
ATγP, a non-hydrolyzable form of ATP, was equally ineffective to increase cell death in 
murine hepatocytes. In contrast to the different types of hepatocytes, ATP caused cell 
death in macrophages at high concentrations.  
ATP as an activator of the inflammasome  
The initial hypothesis was that ATP released during necrotic cell death can activate the 
Nalp3 inflammasome and caspase-1 through binding to the P2X7 receptor and thereby 
stimulate the processing of IL-1β, which then promotes neutrophil infiltration into the 
liver and an aggravation of liver injury by these inflammatory cells (Hoque et al., 2012). 
Although an activation of the Nalp3 inflammasome and a caspase-1-dependent 
processing of proIL1β could be confirmed (Williams et al. 2010a), there was no effect of 
endogenous IL-1β on the inflammatory response and liver injury after APAP overdose 
(Williams et al. 2010a). In addition, treatment with very high doses of exogenous IL-1β 
or endotoxin had no effect on APAP-induced liver injury (Williams et al. 2010a &b ). 




(William et al., 2010a) as did various KO mice of the Nalp3 inflammasome components 
(Williams et al., 2011a), animals deficient of various adhesion molecules (Cover et al., 
2006) or NADPH oxidase-deficient mice (James et al., 2003; Williams et al., 2014) . 
Most importantly, the P2X7 inhibitor used by Hoque et al. was shown to inhibit P450 
enzymes and thus protects because it prevents the initiation of injury rather than the 
activation of the inflammasome (Xie et al., 2013). Together, these data strongly argue 
against a relevant contribution of the ATP-activated inflammasome to the injury after 
APAP overdose. Consistent with these in vivo animal data, neutrophil activation in 
human APAP overdose patients occurs only during regeneration but not during the active 
injury phase (Williams et al., 2014) where most DAMPs including ATP are being 
released (McGill et al., 2013; Antoine et al., 2012). In addition, there is virtually no IL-1β 
formation in humans during APAP hepatotoxicity suggesting that also in humans the 
Nalp3 inflammasome is of limited relevance.  
ATP as a direct cytotoxic agent  
Recently, a second hypothesis was introduced. Amaral et al. reported that HepG2 cells 
release ATP after exposure to 20 mM APAP for 0.5-2 hours. The peak levels of ATP 
measured were approximately 10 µM at 0.5 hours (Amaral et al., 2013). Using 10 µM 
and 100 µM ATP, the authors then demonstrated that these doses caused 40% cell death 
in primary mouse hepatocytes isolated from C57Bl/6J mice and in HepG2 cells after 18-
24 h exposure (Amaral et al., 2013). Based on these findings, the authors concluded that 
ATP, in addition to activating the inflammasome through purinergic receptors on 
macrophages, can also act as a direct cytotoxic agent against hepatocytes (Amaral et al., 




to be expressed on hepatocytes (Gonzales et al., 2007; Emmett et al., 2008). However, in 
our hands, ATP in concentrations from 10 µM up to 10 mM did not affect cell viability in 
primary mouse hepatocytes isolated from the same strain of mice, nor did treatment with 
a non-hydrolyzable ATP analogue (ATγP). Moreover, 5 mM APAP caused significant 
cell death at 9 h post-treatment in our primary mouse hepatocytes, but various 
concentrations of ATP or ATγP had no significant impact on this APAP-induced cell 
death. Cell death in these experiments as indicated by LDH or ALT release was 
confirmed by additional parameters such as propidium iodide staining, as measure of 
necrosis, and by the JC-1 assay, which indicates the mitochondrial membrane potential. 
Thus, ATP at levels that would be present in the extracellular milieu in vivo for only a 
short period of time and at concentrations which are one to several orders of magnitude 
beyond physiological levels could not kill mouse hepatocytes over a 24 h exposure time. 
Furthermore, there was no evidence that the same physiological or supraphysiological 
concentrations of ATP or ATγP could enhance APAP-induced cell death. Based on these 
findings, we have to conclude that ATP is not a direct cytotoxic agent during APAP-
induced cell death of cultured murine hepatocytes. In contrast, some cytotoxicity was 
observed in murine macrophages exposed to supraphysiological concentrations of ATP 
confirming the idea that ATP could potentially be toxic in vitro, but only under 
circumstances largely irrelevant to human biology. Additional experiments with different 
hepatocyte cell types confirmed these findings. First, the metabolically competent human 
hepatocyte cell line HepaRG (Guillouzo et al., 2007), which is sensitive to APAP toxicity 
(MiGill et al., 2011), could not be killed by ATP alone, and ATP could not enhance 




known to have very low drug metabolizing enzyme levels (Wilkening et al., 2003) and 
are thus mostly resistant to APAP-induced necrosis (MiGill et al., 2011), was not affected 
by ATP alone or in combination with APAP. Finally, primary human hepatocytes, which 
were sensitive to APAP (Xie et al, 2014), did not show loss of cell viability with ATP 
alone and did not show more cell death when ATP was combined with APAP. In 
summary, our data consistently demonstrated in 4 different types of hepatocytes (human 
and mouse) that extracellular ATP was unable to directly cause cell death or aggravate 
APAP-induced cell death. Thus, it is unlikely that ATP released from necrotic cells can 
significantly affect cell death in the liver during APAP hepatotoxicity or other 
pathophysiologies that are characterized by extensive necrosis. APAP-induced cell death 
is clearly dominated by intracellular events caused by reactive metabolite formation, 
mitochondrial dysfunction and oxidant stress rather than extracellular mediators such as 
ATP. However, DAMP-induced cytokine formation in vivo can affect intracellular 
signaling events and enhance cell death (Bourdi et al., 2002) or recruit inflammatory cells 







Chapter 5. Time Course of Acetaminophen-protein Adducts 
and Acetaminophen Metabolites in Circulation of Overdose 













This section is adapted from Xie et.al (2015), “Time course of acetaminophen-protein 
adducts and acetaminophen metabolites in circulation of overdose patients and in 






It has been suggested that acetaminophen (APAP)-protein adducts can be measured in 
circulation to diagnose APAP-induced liver injury. However, the full-time course of 
plasma adducts has not been studied specifically in early-presenting overdose patients. In 
fact, surprisingly little work has been done on the metabolism of APAP after overdose in 
general. 
We measured APAP, five APAP metabolites and APAP-protein adducts in plasma 
samples from early- and late-presenting overdose patients, and APAP-protein adducts in 
culture medium from HepaRG cells. 
In contrast to earlier rodents studies, we found that APAP-protein adducts were lower at 
early time points and peaked around the time of peak liver injury, suggesting that these 
adduct levels may take longer to become elevated or remain elevated than previously 
thought. 
APAP and its major metabolites were elevated in plasma at early time points and rapidly 
decreased. 
Although clinical measurement of APAP-protein adducts holds promise as a diagnostic 
tool, we suggest caution in its interpretation in very early-presenting patients. Our data 
also support the idea that sulfation is saturated even at low doses but glucuronidation has 








At recommended doses, acetaminophen (APAP) is a safe and effective drug for the 
management of pain. However, overdose of APAP can cause severe acute liver injury 
and liver failure. It is responsible for almost 80 000 emergency department visits in the 
U.S. each year (Budnitz et al., 2011), as well as 26 000 hospitalizations and nearly 500 
deaths (Nourjah et al., 2006) (Nourjah et al., 2006). In fact, APAP hepatotoxicity is one 
of the most common etiologies of acute liver failure (Lee, 2012). 
The metabolism and pharmacokinetics of APAP after therapeutic doses were first studied 
in detail in the 1960s; our understanding of APAP metabolism has grown considerably 
since that time (McGill & Jaeschke, 2013). The bioavailability of orally administered 
APAP is about 80%. The drug is rapidly absorbed from the lumen of the small intestine, 
achieving maximum plasma concentration within 0.5–1.5 h in fasted subjects. 
Glucuronidation and sulfation are the major elimination pathways. Sulfation is saturated 
even at therapeutic doses (Clements et al., 1984; Prescott, 1980), so glucuronidation is 
dominant. In total, about 50–70% of a pharmacological dose is glucuronidated, while 25–
35% undergoes sulfation. A much smaller percentage of the dose (5–10%) is converted to 
the reactive intermediate N-acetyl-p-benzoquinone imine (NAPQI) by cytochrome P450 
enzymes. NAPQI binds to the cysteine sulfhydryl group on glutathione (GSH) and can 
also bind to protein sulfhydryl groups, even after low doses (Heard et al., 2011; McGill 
et al. 2013). Most of the APAP-GSH is broken down to mercapturic acid and cysteine 
conjugates and the resulting APAP-N-acetylcysteine (APAP-NAC), APAP-cysteine 
(APAP-cys), as well as APAP-protein adducts can be measured in plasma and urine as 




It has been suggested that APAP overdose can be rapidly diagnosed by measuring 
protein-derived APAP-cysteine adducts (hereafter referred to as “APAP-protein adducts”) 
in serum from both adults (Davern et al., 2006) and children (James et al., 2008), but 
some aspects of the time course and mechanism of release of these adducts have not yet 
been investigated in humans. In particular, time course experiments in mice suggest that 
the concentration of APAP-protein adducts in circulation increases rapidly after APAP 
treatment and peaks even before the onset of liver injury (McGill et al., 2013). However, 
the full-time course of circulating adducts, beginning before the peak of injury, has not 
been characterized in APAP overdose patients. Also, despite our extensive knowledge of 
APAP metabolism after therapeutic doses, surprisingly few studies have specifically 
examined APAP metabolism after overdose. 
To better understand the appearance of APAP-protein adducts in circulation and APAP 
metabolism after overdose, we collected plasma samples from patients with a recent 
history of APAP overdose. Patients were grouped as either early or late presenters on the 
basis of plasma APAP levels. We measured the five major metabolites of APAP, APAP-
glucuronide (APAP-gluc), APAP-sulfate (APAP-sulf), APAP-GSH, free APAP-cys, and 
APAP-NAC, as well as APAP-protein adducts, in these samples using mass spectrometry. 
Our results suggest that APAP-protein adducts increase later than expected in humans 
and that clinical measurements of these adducts should be interpreted with caution. The 








Patient enrollment and categorization 
Patients presenting to the University of Kansas Hospital in Kansas City, Kansas were 
studied prospectively. The diagnosis of APAP overdose was made by a physician. All 
patients or next of kin were informed of the study purpose and protocol and signed a 
consent form. The criteria for study inclusion were reported history of APAP overdose, 
high plasma APAP levels, or evidence of liver injury (ALT > 1000 U/L and prothrombin 
time ≥ 18 s). All patients met at least two of these criteria. Patients were excluded if 
there was reasonable evidence that their liver injury was due to some other etiology (e.g. 
viral hepatitis, alcoholic hepatitis, etc.). Because APAP has a short half-life, the patients 
were grouped into early or late time points on the basis of plasma APAP concentration. 
Patients considered “early” had a reported history of APAP overdose and relatively high 
plasma APAP levels (>25 µg/mL; the top of the therapeutic range) with little or no 
evidence of liver injury (<100 U/L ALT) at the time of presentation, which is known to 
develop at later time points in humans (McGill et al., 2012; Singer et al., 1995). Patients 
considered “late” had lower plasma APAP levels (1–25 µg/mL), coupled with evidence 
of liver injury (ALT ≥ 100 U/L in the first study sample, peak ALT > 1000 U/L and peak 
prothrombin time ≥18 s). A total of  25 µg/mL was chosen as our cut-off, because it is at 
the top of the range of serum concentrations that is normally seen after therapeutic doses 
of APAP. Our assumption is that patients with higher levels likely exceeded the 
maximum recommended dose of APAP. All patients were treated with either oral or i.v. 




were approved by the internal review board (IRB) of the University of Kansas Medical 
Center. 
Patient sample collection and handling 
Blood samples were drawn in vacuum tubes dry-coated with heparin or EDTA. Plasma 
was obtained by centrifugation and aliquots were stored at −80 °C for later analysis. 
Biochemistry 
Clinical parameters, including alanine aminotransferase (ALT), INR, bilirubin and 
creatinine, were measured and calculated in the clinical lab at the University of Kansas 
Hospital using standard methods and reagents. Lactate dehydrogenase (LDH) release was 
measured as previously described (Bajt et al., 2004). 
HepaRG cells 
HepaRG cells were obtained from Biopredic International (Rennes, France). The cells 
were grown and maintained as previously described (McGill et al., 2011). For time 
course experiments, the cells were washed with 1 × PBS to remove the maintenance 
medium and treated with 20 mM APAP dissolved in DMSO-free Williams' E medium 
containing 10% FBS, insulin and penicillin/streptomycin. 
Analysis of APAP and metabolites in human plasma and HepaRG cells 
Protein-derived APAP-cysteine adducts (APAP-protein adducts) were measured in 
HepaRG cells as previously described (McGill et al., 2011). Before measurement of 
APAP-protein adducts in plasma or cell culture medium, the samples were prepared as 




including free APAP-cys, were removed by dialysis followed by filtration through size 
exclusion columns to obtain total plasma protein. The proteins were then digested 
overnight using a mixture of proteases, followed by precipitation of the proteases and 
filtration to ensure that the samples were clean enough for HPLC. A detailed description 
of the basic method for APAP-protein adduct measurement has recently been published 
(Cook et al., 2015). 
For plasma samples, the following reference standards and deuterated internal standards 
were obtained from Toronto Research Chemicals Inc. (Toronto, Ontario, Canada): 4-
acetamidophenyl β-D-glucuronide sodium salt (APAP-gluc, 98%), 4-acetaminophen 
sulfate potassium salt (APAP-sulf, 98%), 3-(N-acetyl-l-cystein-S-yl)-acetaminophen 
disodium salt (APAP-NAC, 95%), 3-cysteinylacetaminophen trifluoroacetic acid salt 
(APAP-cys, 95%), acetaminophen glutathione disodium salt (APAP-glut, 95%), 
acetaminophen-d4 (APAP-d4, 98% chemical purity, 99% isotopic purity), and 4-
acetaminophen-d3 sulfate (APAP-d3-sulf, 98% chemical purity, 99% isotopic purity). 
APAP (analytical standard) and ammonium acetate (≥98%) were obtained from Sigma-
Aldrich Co. (St. Louis, MO). LC-MS grade acetonitrile and methanol were obtained from 
Honeywell Burdick and Jackson (Morristown, NJ). Glacial acetic acid was obtained from 
Spectrum Chemical Manufacturing Corp. (New Brunswick, NJ). Formic acid (88%) was 
obtained from Fisher Scientific (Pittsburgh, PA). Ultrapure water (18.2 MΩ) was 
obtained by passage of deionized water through a Milli-Q Plus filtration system 
(Millipore, Billerica, MA). 
Stock and working solutions of reference standards and internal standards were prepared 




10 µg/mL were prepared by serial dilution. Specified concentrations refer to the free acid 
of salt reference standards. Calibration standards and quality control (QC) samples were 
prepared concurrently with study samples by fortification of 10 µL of analyte-free, 
heparinized human plasma with reference standard working solutions. The calibration 
curve ranged from 0.01 to 100 µg/mL, and QC samples of 0.05, 0.5, 5, and 50 µg/mL 
were included for assessment of accuracy. If necessary, patient samples were diluted for 
quantification within the curve range. 
To maintain equivalence in preparation, methanol-water (1:1, v/v) was used to bring all 
study samples (10-µL aliquots) and fortified calibration and QC samples to a total 
volume of 110 µL. Study samples, calibrators, and QC samples were then fortified with 
40 µL of internal standard working solution containing 2.5 and 25 µg/mL of APAP-d4 
and APAP-d3-sulf, respectively. Plasma proteins were precipitated by the addition of 
acetonitrile (600 µL), and each sample was vortex mixed for 30 s before 15 min of 
centrifugation at 1100 × g. Sample supernatants were transferred to clean tubes, placed in 
a 35 °C water bath, and evaporated to dryness under a 10–15 psi air stream in a Zymark 
TurboVap LV Evaporator. Sample residues were reconstituted in 500 µL of 0.1% 
aqueous formic acid, vortex mixed for 30 s, and centrifuged for 5 min at 1100 × g. The 
supernatants (200 µL) were then carefully removed and transferred to a autosampler vials 
and held at 5 °C until the time of analysis. A 25 µL injection volume was used for 
analysis. 
Sample analysis was performed on an Agilent 1200 Infinity Series HPLC system 
equipped with an Agilent Poroshell 120 EC-C18 column (2.1 × 100 mm ID, 2.7-µm 




spectrometer (Agilent Technologies, Santa Clara, CA) or on a Waters Acquity UPLC 
system equipped with a Waters C18 column and interfaced with a Waters Quattro 
Premier XE triple quadrupole mass spectrometer (Waters Corp., Milford, MA). Sample 
preparation and measurement were the same in both cases. Standard curves were used to 
quantify samples in every run. Chromatographic separation was achieved using 10-mM 
aqueous ammonium acetate, pH 3.5 (A) and methanol (B) at a flow rate of 0.25 mL/min. 
Mobile phase was maintained at 3% B for the first 6.0 min, increased linearly to 35% B at 
9.0 min, maintained at 95% B from 9.1 to 12.0 min, decreased linearly to 3% B at 
12.5 min, and then re-equilibrated at 3% B until 20.0 min. The column compartment was 
maintained at 40 °C, and prepared samples were stored in the autosampler at 5 °C during 
analysis. The mass spectrometer was operated in electrospray ionization mode with 
MRM data acquisition. APAP-sulf and APAP-d3-sulf were monitored in negative 
ionization mode; all other analytes and APAP-d4 were monitored in positive ionization 
mode. The following source conditions were applied: 350 °C gas temperature, 10 L/min 
gas flow, 30 psi nebulizer pressure, 350 °C sheath gas temperature, 9 L/min sheath gas 
flow, 3500 V capillary voltage, and 500 V nozzle voltage. Fragmentor voltage and 
collision energy were optimized for each MRM transition. The following MRM 
transitions (precursor m/z → product m/z) were monitored for quantification: 152.1 →
 110.0 for APAP, 328.1 → 152.1 for APAP-gluc, 230.1 → 150.1 for APAP-sulf, 313.1 →
 208.0 for APAP-NAC, 271.1 → 140.0 for APAP-cys, 457.1 → 140.0 for APAP-GSH, 
156.1 → 114.1 for APAP-d4, and 233.1 → 153.1 for APAP-d3-sulf. Additional 
secondary transitions were monitored for qualitative confirmation of analyte presence. 




software (v. B.04.00, Agilent Technologies, Santa Clara, CA). Calibration curves were 
constructed by plotting the analyte to internal standard chromatographic peak area ratio 
against the known analyte concentration in each calibration standard. APAP-d4 was used 
as the internal standard for APAP, and APAP-d3-sulf was used as the internal standard 
for all other analytes. Linear curve fits were applied for all analytes except APAP-NAC, 
for which a quadratic curve fit was used. Curves were weighted in proportion to the 
reciprocal of the squared analyte concentration. 
Statistics 
Normality was assessed using the Shapiro–Wilk test. For normally distributed data, 
significance was tested using the Student's t-test or one-way analysis of variance 
(ANOVA) for experiments involving two or more groups, respectively. For non-normally 
distributed data, significance was tested using the Mann–Whitney U-test or the Kruskal–
Wallis test for experiments involving two or more groups, respectively. Multiple 
comparisons were performed post-hoc using either Tukey's test or Dunn's test, depending 
upon whether the data were normal or non-normal, respectively. Fisher's Exact test was 





To begin studying the time course of APAP-protein adducts and metabolism of APAP in 




metabolites and APAP-protein adducts in plasma from nine APAP overdose patients who 
presented before the peak of injury as indicated by plasma ALT levels. APAP-GSH 
concentrations were below the lower limit of detection in most samples, indicating that 
most of this conjugate is quickly broken down to APAP-NAC and APAP-cys. However, 
we were able to detect and quantify all of the other metabolites. Consistent with previous 
results, we found that the major metabolite of APAP was APAP-gluc, followed by 
APAP-sulf, APAP-cys and finally by APAP-NAC (Figure 1A and C). APAP and all four 
metabolites were high at the time of study admission, but rapidly decreased (Figure 1A, C, 
E). Surprisingly, although APAP-protein adduct concentrations were already detectable 
at the time of study admission, the peak of circulating adducts was not observed until 
later time points, around the time of peak ALT (Figure 1F). This is different from what 
has been observed in mice (McGill et al., 2013). 
We then sorted 17 APAP overdose patients into early- and late-presenting groups. 
Patients were categorized on the basis of plasma APAP levels because it was difficult to 
ascertain the time of ingestion for many of the patients. APAP has a short circulating 
half-life, and liver injury develops relatively late after APAP overdose. Thus, patients 
presenting early after APAP ingestion with a reported history of overdose will have 
higher plasma APAP concentrations and little or no evidence of liver damage in the first 
sample obtained after study enrollment. On the other hand, patients with a reported 
history of APAP overdose who have lower plasma APAP but signs of liver injury in the 
first study sample are likely to be later presenters. When patient reported time of 
overdose was available, it was found to be consistent with our patient grouping. The time 




(mean: 10 h, range: 5–16 h) and for 10 of the late-presenting patients (mean: 83 h, range: 
3–336 h). Although one patient in the latter group presented to the hospital within 3 h of 
 
Figure 5.4.1 Time courses of APAP, APAP metabolites, and APAP-protein adducts 
in early-presenting overdose patients.  
Plasma APAP, metabolites, and protein adducts were retrospectively measured in plasma 
from APAP overdose patients who presented at least 2 d before the peak of liver injury 
indicated by ALT. (A,C) Plasma concentrations of APAP and APAP metabolites from a 




from a representative patient. (E) Mean plasma levels of APAP-gluc and ALT in all 
patients presenting at least 2 d before the peak of liver injury. (F) Mean APAP-protein 
adducts and ALT in all patients presenting at least 2 d before the peak of liver injury. 





Figure 5.4.2 Plasma APAP and ALT concentrations in the early and late groups.  
Plasma APAP and ALT were measured in the first sample available after study 
enrollment. (A) Plasma APAP. (B) Plasma ALT. Data expressed as mean ± SEM for 6 










the reported time of overdose, it is important to note that this particular patient did not 
enroll in our study for another 24 h. The remaining patients in the late group for whom 
this information is available presented much later. In every case, treatment with NAC 
was immediately started. Although the time frame of APAP use was not available for all 
patients, the patients in the early group tend to be classified by the diagnosing physician 
as acute overdoses (duration of APAP use <48 h) while the late group included a mix of 
acute and chronic (duration of APAP use >48 h) cases. The average plasma APAP and 
ALT levels in the first plasma samples available after the time of study enrollment are 
shown in Figure 2. Other clinical and demographic information for these patients are 
listed in Table 5.4.1. 
We found that the average plasma concentration of APAP-sulf was not significantly 
different between our early and late patients (Figure 3A). Moreover, the APAP-sulf levels 
in these overdose patients were not remarkably different from those previously reported 
in individuals receiving subtoxic or even just therapeutic doses of APAP (Gelotte et al., 
2007; Prescott, 1980) . On the other hand, APAP-gluc levels were much higher in the 
early patients (Figure 3B) and were elevated approximately 20-fold compared with 
previously reported values for APAP-gluc after subtoxic doses. Together, these results 
are in agreement with the earlier findings that both sulfation and renal elimination of 
APAP-sulf are saturated after APAP ingestion and remain so until later time points 
(Clements et al., 1984; Prescott, 1980), while glucuronidation and APAP-gluc 
elimination are not so easily saturated even after overdose because the APAP-gluc levels 
in serum seem to scale with the concentration of APAP. Similar to APAP-sulf, the 





Figure 5.4.3 Plasma APAP metabolite concentrations in the early and late groups. 
Plasma APAP metabolites were measured in the first sample available after study 
enrollment. (A) Plasma APAP-sulf. (B) Plasma APAP-gluc. (C) Plasma APAP-NAC. (D) 
Plasma free APAP-cys. Data expressed as mean ± SEM for 6 early patients and 11 late 




Figure 5.4.4 Plasma APAP-protein adduct concentrations in the early and late 
groups.  
Plasma APAP-protein adducts were measured in the first sample available after study 






Figure 5.4.5 Time course of APAP-protein adduct release and cell death in HepaRG 
cells.  
HepaRG cells were treated with 20 mM APAP for the indicated times. APAP-protein 
adducts were measured in both cell lysates and in the cell culture medium. Cell death was 
assessed by lactate dehydrogenase (LDH) release, as described in the methods section. 





significantly different between groups (Figure 3C and D). Because one would expect a 
saturated metabolic pathway to plateau and the levels of its metabolite products to remain 
unchanged for some time, the latter finding may be in agreement with the idea that the 
GSH pathway is also overwhelmed. 
As we predicted from our time course data, protein adduct levels in plasma were much 
higher in the late-presenting group (Figure 4). These data suggest that the appearance of 
peak levels of APAP-protein adducts may be delayed or evolve over hours or even days 
in humans after overdose, in contrast to rodents which have elevated plasma adducts well 
before any detectable increase in ALT (within 15–30 min after APAP treatment; McGill 
et al., 2013). It is possible to argue that the lower plasma APAP-protein adducts level in 
the early group is due to earlier treatment with NAC, but the fact that APAP-NAC and 
free APAP-cys levels did not differ between groups suggest that this is unlikely to be the 
case. Moreover, these data are from the first available samples obtained after study 
enrollment. Generally, the patients were enrolled on the day of admission and therefore 
had not been receiving NAC for long. Furthermore, we also observed a late increase in 
APAP-protein adducts in culture medium from the human liver cell line HepaRG (Figure 
5), which also differs from what has been reported for primary mouse hepatocytes 
(McGill et al., 2013). Interestingly, however, the adduct concentration in the culture 
medium still increased before an increase in enzyme release (Figure 5), consistent with 









Figure 5.4.6 Schematic of APAP metabolism and APAP-protein adducts release.  
At therapeutic doses, roughly a third of the dose is eliminated by sulfation while two-
thirds is eliminated by glucuronidation. After overdose, sulfation is saturated and a much 
higher percentage is glucuronidated. Furthermore, our data suggest that APAP-protein 




The metabolism and disposition of APAP in humans after therapeutic doses has been 
studied for quite some time. Recently, several groups have even succeeded with studies 
designed to explore the mechanisms of APAP hepatotoxicity in humans (Antoine et al., 
2012; McGill et al., 2012, 2014a,b; Weerasinghe et al., 2014; Williams et al., 2014) 
(Williams et al., 2014). One early advance in this area was the discovery that APAP-
protein adducts can be detected in humans (Hinson et al., 1990; Muldrew et al., 2002; 
Webster et al., 1996). Since then, it has been suggested that the presence of APAP-
protein adducts in serum can be used to diagnose APAP overdose (Davern et al., 2006; 
James et al., 2008). However, there are still gaps in our knowledge about the mechanism 
of appearance of APAP-protein adducts in serum and even the basic metabolism of 
APAP after overdose. It is clear that glucuronidation, sulfation, glutathione conjugation, 
and protein binding all occur in overdose patients, but the kinetics and toxicological 
significance of each is less well understood. Our goal with this study was to develop a 
better understanding of the full-time course of APAP-protein adduct formation and 
APAP metabolism after overdose in humans. A summary of our findings are 
schematically shown in Figure 6. 
Kinetics of plasma APAP-protein adducts after overdose 
In mice, APAP-protein adducts rapidly appear in plasma after APAP treatment (McGill 
et al., 2013). Although it is important to keep in mind that APAP studies in mice are 
usually done under fasting conditions to deplete GSH more quickly and this could affect 
the results, it has also been shown APAP-protein adducts are detectable in serum from 
humans as well as mice even after low doses, which do not cause injury (Heard et al., 




released by cell lysis (Davern et al., 2006; James et al., 2009), it is clear from these 
studies that liver injury is not required for the appearance of adducts in circulation. 
Furthermore, APAP-protein adducts form rapidly in human hepatocytes after APAP 
treatment (Xie et al., 2014). Thus, it would seem likely that plasma adducts would 
increase early in humans after APAP overdose even before the injury begins. If true, then 
the rapid determination of APAP-protein adducts upon patient presentation using a point-
of-care assay could hold considerable clinical value for the early diagnosis of APAP-
induced liver injury. However, the detailed time course of circulating APAP-protein 
adducts had not previously been measured specifically in a cohort of early-presenting 
patients who went on to develop high ALT and other signs of severe liver injury. 
Although individual early-presenting patients have sometimes been included, most work 
to date has focused on later time points in order to determine the half-life of these adducts 
in circulation (James et al., 2009; Heard et al., 2011). Perhaps, the most interesting 
finding from our data is that plasma APAP-protein adducts may rise slowly in humans 
after overdose. This is consistent with the earlier observation that APAP-protein adduct 
peak levels correlate well with ALT (James et al., 2009). Based on this, it is possible that 
APAP overdose patients presenting early will have low plasma APAP-protein adduct 
concentrations. If treatment decisions are made solely on the basis of a rapid point-of-
care assay performed at the time of presentation, such low levels may prevent the proper 
treatment of some patients. Thus, circulating adduct levels should be interpreted carefully. 
Additionally, because plasma APAP and its metabolites are higher at early time points, 
we suggest that the plasma level of the parent drug or a metabolite should also be 




adduct measurement. If both adducts and the APAP or APAP metabolite levels are low, 
then the result is likely to be a true negative. Although this approach may not aid 
diagnosis in every possible case (Bebarta et al., 2014), it is likely to be effective in most 
cases. The results of previous work that suggested that serum APAP levels (i.e. the 
Rumack-Matthews nomogram) are more useful for diagnosis than APAP-protein adducts 
at early time points are in agreement with this idea (James et al., 2008). 
Little is known about the mechanisms of APAP-protein adduct release into circulation. It 
has been shown that APAP-protein adducts appear in the medium of primary mouse 
hepatocytes cultured in the absence of extracellular protein and before the onset of cell 
injury, suggesting that adducts are actively secreted out of hepatocytes into the 
extracellular space, not simply passively released during cell death. However, the actual 
route of secretion is unknown. Furthermore, although it is clear that the release of APAP-
protein adducts into circulation does not require cell death (Heard et al., 2011; McGill et 
al., 2013), there is evidence that cell death can further increase APAP-protein adduct 
levels (McGill et al., 2013). Thus, it seems that the mechanism of adduct release is 
complex. Additional study is needed to better understand this phenomenon. 
Attempts have been made to develop models to determine the time and dose of an APAP 
overdose (Remien et al., 2012). Although it was suggested that APAP-protein adduct 
levels in serum would likely not improve these models (Remien et al., 2012), our data 
showing a clear decrease in APAP and its metabolites while adduct levels were 
increasing (Figure 1) may indicate that the relative amounts of metabolites and adducts 





Importance of glucuronidation after overdose 
It has been known for some time that sulfation is saturated by APAP even after doses in 
the therapeutic range (Clements et al., 1984; Gelotte et al., 2007; Prescott, 1980) . Our 
data support this finding in overdose patients. At therapeutic doses, about one-third of the 
drug undergoes sulfation, while roughly two-third is glucuronidated. The remainder is 
either converted to NAPQI and binds to GSH or proteins, or is excreted unchanged. 
Though it is common to cite these percentages in articles even when referring to overdose 
patients, our results show that glucuronidation plays an even larger role after overdose 
due to saturation of the sulfation pathway. It seems that glucuronidation is not easily 
saturated even after overdose. While the APAP-sulf concentrations measured in our 
patients did not differ much from what has previously been reported after therapeutic 
doses, the APAP-gluc levels were much higher. It is commonly thought that both of these 
phase II elimination pathways, along with glutathionylation, are saturated after APAP 
overdose and that the APAP is then converted to its reactive metabolite (Chun et al., 
2009; McClain et al., 1999; Srivastava et al., 2010). However, it is now clear that the 
reactive metabolite forms and binds to proteins even after therapeutic doses at which 
glucuronidation and glutathionylation are certainly not saturated (Heard et al., 2011; 
McGill et al., 2013). The latter strongly suggests that saturation of these pathways is not 
necessary for NAPQI formation to occur. Nevertheless, glucuronidation is quite 
important. 
The significance of the glucuronidation pathway of APAP elimination has been studied in 
both rodents and humans, though the results have been controversial. Glucuronidation-




than other rat strains (de Morais & Wells, 1989). Consistent with this, early experiments 
with low doses in humans revealed that individuals with Gilbert's syndrome do not 
glucuronidate APAP as well and have higher concentrations of APAP-GSH in urine (de 
Morais et al., 1992). However, these results are in conflict with an earlier experiment 
involving Gilbert's syndrome patients that yielded opposite result(Ullrich et al., 1987). 
The difference in findings between these studies may have been due to differences in 
dose normalization and route of exposure, although later work using an experimental 
design similar to that used in the no-effect study provided support for the idea that 
Gilbert's patients may be at increased risk of APAP hepatotoxicity (Esteban & Pérez-
Mateo, 1999). More recently, Court et al. (2013) found that liver samples from humans 
with polymorphisms in the 3′ untranslated region of UGT1A, particularly rs8330, had 
higher APAP glucuronidation activity. Importantly, they also found that there were fewer 
individuals with these alleles among patients with acute liver failure caused by 
unintentional APAP overdose than among those with acute liver failure from other 
etiologies (Court et al., 2013), which may suggest that a greater ability to glucuronidate 
APAP can protect against the hepatotoxicity caused by overdose. Overall, there is a 
strong case that glucuronidation is the most important route of elimination of APAP, such 
that Gilbert's syndrome patients are likely to be more susceptible to APAP toxicity while 
patients who are better at glucuronidation are less likely to develop APAP-induced liver 
injury. Our data support this conclusion. 
Potential weaknesses 
Our grouping of patients based on serum APAP and ALT levels is a potential weakness 




time from overdose to time of presentation, we did not have complete data. Furthermore, 
we did not collect data concerning the time from overdose to NAC treatment or other 
basic patient information, such as the dose of APAP taken, which could affect the 
metabolite and adduct levels that we measured. This should be kept in mind when 
interpreting the results presented in this article. 
Our data suggest that plasma APAP-protein adducts increase slowly in humans in 
contrast to mice, and this may have important implications for the rapid clinical 
measurement of APAP-protein adducts in early-presenting patients. Moreover, our data 
confirm that the sulfation pathway is quickly saturated after exposure to APAP, but 
indicate that glucuronidation is a much higher capacity system. Overall, however, the 
results of this study provide additional support for the idea that glucuronidation is the 
















Chapter 6. Inhibitor of Apoptosis Signal-regulating Kinase 1 



















This section is adapted from Xie et.al (2015), “Inhibitor of apoptosis signal-regulating 
kinase 1 protects against acetaminophen-induced liver injury”, Toxicology and Applied 






Metabolic activation and oxidant stress are key events in the pathophysiology of 
acetaminophen (APAP) hepatotoxicity. The initial mitochondrial oxidative stress 
triggered by protein adduct formation is amplified by c-jun-N-terminal kinase (JNK), 
resulting in mitochondrial dysfunction and ultimately cell necrosis. Apoptosis signal-
regulating kinase 1 (ASK1) is considered the link between oxidant stress and JNK 
activation. The objective of the current study was to assess the efficacy and mechanism 
of action of the small-molecule ASK1 inhibitor GS-459679 in a murine model of APAP 
hepatotoxicity. APAP (300 mg/kg) caused extensive glutathione depletion, JNK 
activation and translocation to the mitochondria, oxidant stress and liver injury as 
indicated by plasma ALT activities and area of necrosis over a 24 h observation period. 
Pretreatment with 30 mg/kg of GS-459679 almost completely prevented JNK activation, 
oxidant stress and injury without affecting the metabolic activation of APAP. To evaluate 
the therapeutic potential of GS-459679, mice were treated with APAP and then with the 
inhibitor. Given 1.5 h after APAP, GS-459679 was still protective, which was paralleled 
by reduced JNK activation and p-JNK translocation to mitochondria. However, GS-
459679 treatment was not more effective than N-acetylcysteine, and the combination of 
GS-459679 and N-acetylcysteine exhibited similar efficacy as N-acetylcysteine 
monotherapy, suggesting that GS-459769 and N-acetylcysteine affect the same pathway. 
Importantly, inhibition of ASK1 did not impair liver regeneration as indicated by PCNA 
staining. In conclusion, the ASK1 inhibitor GS-459679 protected against APAP toxicity 
by attenuating JNK activation and oxidant stress in mice and may have therapeutic 






Acetaminophen (APAP) is a widely used analgesic and antipyretic. A therapeutic dose of 
APAP is safe and effective while an overdose can cause severe liver injury in animals 
and humans (Larson, 2007 and McGill et al., 2012a). Hepatotoxicity is initiated by 
formation of a reactive metabolite, N-acetyl-p-benzoquinone imine, which is detoxified 
by glutathione but also binds to cellular proteins ( Cohen et al., 1997). Although 
formation of protein adducts, especially in mitochondria, is a critical event in the 
pathophysiology (Tirmenstein and Nelson, 1989), it is not sufficient to cause cell death 
(Jaeschke and Bajt, 2006). The current hypothesis is that protein binding induces 
mitochondrial dysfunction including inhibition of mitochondrial respiration (Meyers et al., 
1988) and formation of reactive oxygen species (ROS) (Jaeschke, 1990) and peroxynitrite 
( Hinson et al., 1998 and Cover et al., 2005). This oxidant stress together with lysosomal 
iron taken up into the mitochondria by the Ca2 + uniporter (Kon et al., 2010), leads to the 
opening of the mitochondrial membrane permeability transition (MPT) pore and collapse 
of the membrane potential ( Kon et al., 2004, Reid et al., 2005, Ramachandran et al., 
2011a and LoGuidice and Boelsterli, 2011). The massive loss of mitochondrial function 
triggers necrotic cell death (Gujral et al., 2002). A number of therapeutic interventions 
that accelerated the recovery of mitochondrial glutathione and improved the 
detoxification of mitochondrial ROS and peroxynitrite provided clear evidence for the 
critical role of the mitochondrial oxidant stress in the mechanism of cell death ( Knight et 
al., 2002, James et al., 2003, Ramachandran et al., 2011b and Saito et al., 2010b). 
However, it remained unclear how this extensive mitochondrial oxidant stress ultimately 




Studies during the last decade aimed at elucidating intracellular signaling events have 
demonstrated a critical role of the mitogen-activated protein kinase (MAPK) c-jun-N-
terminal kinase (JNK) in APAP-induced cell death in mice (Gunawan et al., 2006, 
Henderson et al., 2007 and Latchoumycandane et al., 2007) and in human hepatocytes 
(Xie et al., 2014). Importantly, JNK was not only activated (phosphorylated) in the 
cytosol, p-JNK also translocated to the mitochondria (Hanawa et al., 2008) and amplified 
the mitochondrial oxidant stress (Saito et al., 2010a) through binding to an anchor protein 
in the outer mitochondrial membrane (Win et al., 2011). It was also shown that an early 
mitochondrial oxidant stress triggered JNK activation (Hanawa et al., 2008 and Saito et 
al., 2010a). However, JNK is not a redox-sensitive kinase. In fact, the upstream kinases, 
apoptosis signal-regulating kinase 1 (ASK1) (Nakagawa et al., 2008) and mixed-lineage 
kinase 3 (MLK3) (Sharma et al., 2012) have been identified as critical upstream 
regulators of JNK activation. Oxidant stress can release ASK1 from its complex with 
reduced thioredoxin by oxidation of thioredoxin resulting in the liberation of the active 
kinase (Saitoh et al., 1998). Because ASK1 is thought to be mainly responsible for 
sustained activation of JNK, the substantial reduction in APAP-induced liver injury in 
ASK1-deficient mice demonstrated the critical role of ASK1 in the pathophysiology 
(Nakagawa et al., 2008). Recently a potent and selective small molecule inhibitor of 
ASK1 with properties amenable for in vivo efficacy testing in rodents was developed 
(Gerczuk et al., 2012 and Toldo et al., 2012). This inhibitor enabled us to test if 
pharmacologic inhibition of ASK has therapeutic potential for treating APAP 




6.3 Materials and methods 
 
Animals 
8 week old male C57Bl/6 mice were acquired from Jackson Laboratories for the 
experiments. Animals were housed in a controlled environment with a 12 hour light/dark 
cycle and free access to food and water. Animals were acclimatized for at least 3 days 
and fasted overnight before experiments. All experimental protocols were approved by 
the Institutional Animal Care and Use Committee of the University of Kansas Medical 
Center. 
Inhibitors 
GS-459679 and GS-444217 are potent and selective ATP competitive inhibitors of ASK1 
developed by Gilead Sciences, Inc., Foster City, CA (Breckenridge et al., manuscript in 
preparation). In a competitive, time-resolved fluorescence resonance energy transfer 
immunoassay, GS-459679 and GS-444217 directly inhibit ASK1 kinase activity with 
IC50 (concentration that inhibits ASK1 kinase by 50%) values of 6.1 and 2.9 nM, 
respectively. One micromolar GS-459679 results in 99% inhibition of the ASK1 kinase 
but does not inhibit 20 other kinases implicated in cellular stress signaling (Gerczuk et al., 
2012). 
Experimental design 
For pre-treatment studies, animals were administered either the ASK1 inhibitor GS-
459679 (ASK1i) (10 or 30 mg/kg), or vehicle (55% PEG in H2O) 30 min prior to 
administration of APAP (300 mg/kg, i.p.). Animals were euthanized 0.5, 6 or 24 h after 
APAP. For post-treatment experiments, animals were administered APAP (300 mg/kg, 




ASK1i + NAC or vehicle (saline) at 1.5 or 3 h after APAP. Animals were allowed access 
to regular food at 6 h after APAP treatment; the animals were euthanized at 24 h. For 48 
h experiments evaluating liver regeneration, animals were given back food (control diet 
or diet containing 0.2% of the ASK1 inhibitor GS-444217) 6 h after APAP administration. 
At the end of the experiments, animals were anesthetized with isoflurane and blood was 
drawn from vena cava into heparinized syringes for determination of alanine 
aminotransferase (ALT) activity. The liver was excised and rinsed in saline before being 
divided for histology and subcellular fractionation, and the rest being snap frozen in 
liquid nitrogen and subsequently stored at − 80 °C. 
Histology 
Formalin-fixed tissue samples were embedded in paraffin and 4 μm sections were cut. 
Replicate sections were stained with hematoxylin and eosin (H&E) to evaluate necrosis 
as described (Gujral et al., 2002). 
Measurement of GSH and GSSG 
Total soluble GSH and GSSG were determined in the liver homogenate with a modified 
method of Tietze (Jaeschke and Mitchell, 1990). In brief, the frozen tissue was 
homogenized at 0 °C in 3% sulfosalicylic acid containing 0.1 mM EDTA. For 
measurement of GSSG, GSH was trapped with 10 mM N-ethylmaleimide. The sample 
was centrifuged after dilution with 0.01 N HCl and the supernatant was further diluted 
with 100 mM potassium phosphate buffer (KPP), pH 7.4. The samples were then assayed 
using dithionitrobenzoic acid. All data are expressed as GSH-equivalents. 




Mitochondria and cytosolic fractions were isolated using differential centrifugation as 
described (Xie et al., 2013). Western blots were performed as described in detail (Bajt et 
al., 2000 and Du et al., 2013), using the following antibodies: a rabbit anti-JNK antibody 
(Cell signaling Technology, Danvers, MA) and a rabbit anti-phospho-JNK antibody 
#4668, which recognizes Thr183/Tyr185 phosphorylated JNK1/2 protein (Cell Signaling 
Technology, Danvers, MA). A horseradish peroxidase-coupled donkey anti-rabbit IgG 
(Santa Cruz) was used as secondary antibody. Proteins were visualized by enhanced 
chemiluminescence (Amersham Pharmacia Biotech. Inc., Piscataway, NJ). 
Statistics 
All data are presented as mean ± SE. For normally distributed data, comparisons were 
made between two groups using Student's t-test, or between three or more groups using 
one-way analysis of variance (ANOVA) with Tukey's post-hoc test. For non-normally 
distributed data, comparisons were made between two groups using the Mann–Whitney 
U-test, or between three or more groups using the Kruskal–Wallis test with Dunn's 
multiple comparisons. All statistical tests were performed using SigmaPlot software 







Pharmacological inhibition of ASK1 protects against APAP-induced liver injury 
As an initial attempt to investigate the effect of ASK1 inhibition on APAP hepatotoxicity, 
mice were treated with 10 or 30 mg/kg of GS-459679 (ASK1i), 30 min prior to 
administration of 300 mg/kg APAP. Liver injury was then examined 6 and 24 h later. 
APAP induced significant liver injury as indicated by the increase in plasma ALT 
activities, which were elevated at 6 h and further increased by 24 h (Fig. 1A). This was 
accompanied by development of centrilobular necrosis (Figs. 1B, C). Pretreatment with 
10 mg/kg ASK1i did not achieve significant protection against APAP hepatotoxicity up 
to 24 h. However, pre-treatment with 30 mg/kg ASK1i resulted in a pronounced 
protection as indicated by the 93% (6 h) and 95.2% (24 h) reduction in plasma ALT 
activities (Fig. 1A) and 100% (6 h) and 84% (24 h) less centrilobular necrosis (Figs. 1B, 
C), indicating that pharmacological blockage of ASK1 activity could prevent APAP-
induced liver injury. Evaluation of plasma concentrations of ASK1i at 6 h post-APAP 
administration confirmed a higher exposure of ASK1i in animals administered 30 mg/kg 
compared to 10 mg/kg (Supplemental Fig. 1). Since the 30 mg/kg dose seemed to be 
most effective, this dose was used for further experiments. In order to investigate whether 
the ASK1i treatment protects against the injury by inhibiting drug metabolism, short term 
experiments were carried out by measuring the depletion of liver GSH at 30 min after 
APAP as a surrogate marker for NAPQI formation. APAP caused 86% depletion of 
hepatic GSH levels within 30 min. The initial loss of liver GSH was comparable in 
animals treated with APAP alone or in combination with either the vehicle or ASK1i, 





Figure 6.4.1 Protective effect of the ASK1 inhibitor GS-459679 against APAP-
induced liver injury.  
C57BL/6 mice were pretreated with either 10 or 30 mg/kg GS-459679 or an equivalent 
dose of the vehicle (55% PEG in water) 30 min before 300 mg/kg APAP administration. 
(A) Plasma alanine aminotransferase (ALT) activities measured at 6 and 24 h after APAP 
treatment. (B) Quantitation of the areas of necrosis in H&E-stained liver sections. (C) 
Representative sections from each group with H&E staining. Data represent means ± SE 
of n = 4–11 animals per group. *P < 0.05 compared with control (Ctrl) groups, # P < 0.05 
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C57BL/6 mice were pretreated with either 10 or 30 mg/kg GS-459679 or an equivalent 
dose of the vehicle (55% PEG in water) 30 min before 300 mg/kg APAP administration. 
(A) Plasma alanine aminotransferase (ALT) activities measured at 6 and 24 h after APAP 
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Figure 6.4.2 Effect of ASK1 inhibitor GS-459679 on APAP-induced GSH depletion. 
 Mice were treated with 30 mg/kg GS-459679 or equivalent amount of vehicle (55% PEG 
in water) 30 min before 300 mg/kg APAP administration. GSH levels (μmol/g liver) were 
measured 30 min after APAP treatment. Data represent means ± SE on n = 3–4 animals 





Figure 6.4.3 Effect of the ASK1 inhibitor GS-459679 on hepatic GSH and GSSG 
levels after APAP treatment.  
Mice were treated with 30 mg/kg GS-459679 or equivalent amount of vehicle (55% PEG 
in water) 30 min before 300 mg/kg APAP administration. GSH levels were measured 
either 6 or 24 h after APAP treatment. (A) Total liver glutathione (GSH + GSSG) in 
μmol/g liver. (B) Glutathione disulfide (GSSG) in nmol/g liver. (C) GSSG-to-GSH ratio. 
Data represent means ± SE of n = 4–7 animals per group.*P < 0.05 compared with 





Assessment of GSH content and oxidant stress (GSSG-to-GSH ratio) after APAP 
treatment indicated a partial recovery of hepatic GSH levels at 6 and 24 h (Fig. 3A), a 
significant increase in GSSG levels at 24 h (Fig. 3B) and a significantly higher GSSG-to-
GSH ratio at 6 and 24 h (Fig. 3C). Treatment with 30 mg/kg ASK1i remarkably enhanced 
the recovery of GSH levels (Fig. 3A) and prevented (6 h) or attenuated the oxidant stress 
(24 h) (Fig. 3C). 
ASK1 inhibition prevents activation of JNK subsequent to APAP overdose 
JNK activation has been implicated in APAP hepatotoxicity and ASK1 is suggested to 
function upstream of JNK in this pathological context (Nakagawa et al., 2008). To 
confirm the mechanism of action of the pharmacological ASK inhibitor, the next series of 
experiments evaluated JNK activation after APAP overdose. APAP treatment caused 
significant JNK activation as demonstrated by elevated levels of the Thr183/Tyr185 
phosphorylated protein, which peaked by 6 h and decreased by 24 h (Fig. 4A). 
Pretreatment with the ASK1i almost completely prevented JNK activation at 6 h (Fig. 
4A). The changes in JNK phosphorylation were not due to alterations in total JNK 
protein, since these were unaltered at both 6 and 24 h after APAP (Fig. 4A). Quantitative 
densitometric analysis confirmed the changes in the p-JNK and total JNK levels (Figs. 4B, 
C). 
Inhibition of ASK1 prevents APAP-induced translocation of JNK to mitochondria 
JNK translocation to mitochondria is a key mechanistic feature of APAP-induced 
hepatotoxicity and mitochondrial permeability transition (Hanawa et al., 2008). Since 




Figure 6.4.4 Effect of the ASK1 inhibitor on JNK activation.  
Western blot analysis (A) of p-JNK and total JNK in the cytosolic fraction of livers from 
untreated mice (Ctrl), mice treated with 30 mg/kg ASK1 inhibitor or mice treated with 
the same volume of vehicle (55% PEG in water) 30 min prior to 300 mg/kg of APAP 
administration. Liver samples were obtained 6 or 24 h after APAP treatment. 
Densitometric quantification was performed on bands of p-JNK (B) and total JNK (C). 
Data represent means ± SE of n = 4 animals. *P < 0.05 compared with control groups. # 




mitochondrial JNK translocation was examined. Treatment with APAP resulted in 
translocation of activated JNK (p-JNK) to the mitochondria by 6 h and this was 
significantly inhibited by ASK1i pretreatment (Fig. 5). The APAP-induced elevation in 
p-JNK was accompanied by increases in total JNK in mitochondria and this was 
prevented by administration of ASK1i (Fig. 5). This suggests that JNK translocation to 
mitochondria occurs subsequent to activation, implying that ASK1 inhibition in the 
context of APAP overdose prevents JNK activation and downstream translocation of p-
JNK to mitochondria. 
ASK1i administration can protect against liver injury even when given after APAP 
overdose 
To examine if ASK1i administration was also effective in a therapeutic setting, the next 
series of experiments compared ASK1i with N-acetylcysteine, which is the current 
standard of care in the clinic for APAP overdose. Animals treated with a single dose of 
500 mg/kg NAC 1.5 h after APAP were significantly protected against liver injury at 24 h 
as indicated by both ALT activities and area of necrosis (Fig. 6A). However, this 
protection was significantly eroded when NAC was administered 3 h after APAP, 
although ALT levels were still significantly less than controls (Fig. 6A). Animals treated 
with ASK1i 1.5 h after APAP also showed significant protection against liver injury 
when compared to vehicle-treated animals but when ASK1i administration was delayed 
to 3 h post APAP, no protection against injury was evident (Fig. 6B). When animals were 
treated with both NAC and ASK1i, protection was almost complete when the 
combination was given at 1.5 h after APAP (Fig. 6C). However, delaying the drug 





Figure 6.4.5 Western blots and densitometric analysis of p-JNK translocation to the 
mitochondria at 6 h.  
Mice were treated with 30 mg/kg ASK1 inhibitor GS-459679 or the vehicle (55% PEG in 
water) 30 min before 300 mg/kg APAP injection. Western blotting was performed for p-
JNK and total JNK in mitochondria (A). Densitometric quantification was carried out on 
band intensity of both total JNK (B) and p-JNK (C). Data represent means ± SE of n = 4 
animals per group. *P < 0.05 compared with control (Ctrl) group, # P < 0.05 compared 




Figure 6.5.6 Effect of ASK1 inhibitor GS-459679 post-treatment against APAP 
hepatotoxicity at 24 h.  
Mice were treated with 500 mg/kg N-acetylcysteine (NAC) (A), 30 mg/kg ASK1i (B) 
and the combination of both (C) either 1.5 or 3 h after 300 mg/kg of APAP 
administration. The vehicle for NAC was PBS, for ASK1i was 55% PEG, and for ASK1i 
+ NAC it was PBS + 55% PEG. Plasma ALT activities and the areas of necrosis were 
quantified. Data represent means ± SE of 3–5 animals per group and time point. *P b 





negated this protection. This suggests that ASK1 inhibition is only effective early after 
APAP administration (within 1.5 h in the mouse) and loses its efficacy relatively rapidly 
after that time. 
ASK1i administration after APAP overdose can also prevent JNK activation in the 
cytosol and its translocation to the mitochondria. To examine if the mechanism of 
protection by ASK1i 1.5 h post treatment also involved prevention of JNK activation, 
cytosolic JNK activation and its translocation to mitochondria were examined by western 
blotting at 6 h after APAP. The APAP-induced JNK activation in the cytosol was 
significantly reduced by NAC, ASK1i or NAC + ASK1i post treatment, all of which also 
effectively prevented p-JNK translocation to mitochondria (Fig. 7). To evaluate the 
reason for the limited therapeutic window for the ASK1i inhibitor, early JNK activation 
and mitochondrial p-JNK translocation were determined (Fig. 8). Limited APAP-induced 
JNK activation in the cytosol was observed as early as 1 h with almost no p-JNK 
translocation to the mitochondria. However, by 2 h, massive JNK activation and 
extensive mitochondrial p-JNK translocation had occurred (Fig. 8). This suggests that 
ASK1 inhibition is only effective if it occurs before mitochondrial p-JNK translocation. 
ASK1 inhibitor administration does not impair liver regeneration after APAP 
A major concern about inhibition of the JNK pathway is the fact that it may lead to 
impairment of liver regeneration (Schwabe et al., 2003). To test whether pharmacological 
inhibition of ASK1 reduces the regenerative capacity of the liver, expression of 
proliferating cell nuclear antigen (PCNA), which is a marker of regeneration, was 





Figure 6.5.7  Effect of ASK1 inhibitor GS-459679 post-treatment on APAP-induced 
JNK activation.  
Western blots (A) and densitometry analysis of p-JNK in the cytosolic (B) and 
mitochondrial (C) fractions. Mice were treated with 500 mg/kg N-acetylcysteine (NAC) 
(A), 30 mg/kg ASK1i (B) and the combination of both (C) 1.5 h after administration of 
300 mg/kg APAP. The vehicle for NAC was PBS, for ASK1i was 55% PEG in water, 
and for ASK1i + NAC it was PBS + 55% PEG. Data represent means ± SE of 3–5 




Figure 6.5.8 Time course of JNK activation after APAP treatment.  
P-JNK was determined in cytosol (A, B) and in mitochondrial fraction (C, D) after 
treatment with 300 mg/kg APAP. Data represent means ± SE of 3 animals per group. *P 





Figure 6.5.9 Effect of the ASK1 inhibitor on the regeneration response after APAP-
induced liver injury.  
Proliferating cell nuclear antigen (PCNA) levels was determined by western blotting (A) 
and immunohistochemistry (C) 24 h after APAP in animals treated either with vehicle 
(55% PEG in water) or 30 mg/kg ASK1 inhibitor 1.5 h after APAP. Densitometry data (B) 
represent means ± SE of 4 animals per group. *P < 0.05 compared with control (Ctrl) 





Figure 6.5.10 Effect of chronic ASK1 inhibitor (GS-444217) treatment on the 
regeneration response after APAP-induced liver injury.  
Proliferating cell nuclear antigen (PCNA) levels were determined by western blotting (A) 
and immunohistochemistry (C) 48 h after APAP in animals fed an ASK1 inhibitor-
containing diet or control diet beginning at 6 h after 300 mg/kg APAP. Densitometry data 
(B) represent means ± SE of 4 animals per group. *P < 0.05 compared with control (Ctrl) 





24 h, an effect which was amplified by administration of ASK1i either 1.5 h post-
treatment (Figs. 9A, B) or 30 min pretreatment (data not shown). Histological assessment 
of PCNA staining confirmed the western blot data (Fig. 9C). We also evaluated if 
continuous inhibition of ASK1 following APAP-induced liver injury impaired liver 
regeneration. To that end, animals were administered APAP and then 6 h later provided 
food with 0.2% by weight of the ASK1 inhibitor GS-444217 and PCNA staining was 
evaluated 48 h post-APAP administration. GS-444217 was utilized for this study because 
it has excellent absorption properties such that high steady state plasma concentrations 
are achieved when it is administered in rodent chow (Supplemental Fig. 2 and Gilead 
unpublished data). Consistent with the data from pretreatment or post-treatment of ASK1i 
(GS-459679), the increased PCNA expression was not impaired by GS-444217 in the diet 
following APAP administration (Figs. 10A, B). These results were confirmed by PCNA 
staining in histological sections (Fig. 10C). We confirmed that GS-444217 had a similar 
protective effect on APAP-induced liver injury as GS-459679 when administered 30 min 
prior to APAP (Supplemental Fig. 3). Together, these data suggest that ASK1 inhibition 











The objective of the investigation was to evaluate the protective effect of the ASK1 
inhibitor GS-459679 in a murine model of APAP hepatotoxicity. Our data showed that 
pretreatment with the ASK1 inhibitor and treatment during a limited therapeutic window 
after APAP overdose attenuated liver injury. 
The ASK1 inhibitor protects against APAP hepatotoxicity by inhibition of JNK 
ASK1 is a serine/threonine protein kinase, which can activate the MAPK cascade 
resulting in the activation of p38 and JNK. ASK1 is expressed in both cytoplasm and 
mitochondria and can be activated by ROS or cytokines such as tumor necrosis factor-α 
(Ichijo et al., 1997, Nishitoh et al., 1998 and Matsuzawa et al., 2005). Under basal 
conditions, ASK1 is bound and repressed by the reduced form of thioredoxin (Saitoh et 
al., 1998). However, during oxidative stress, ASK1 is released from the oxidized form of 
thioredoxin and activated by an autocatalytic mechanism (Liu et al., 2000), allowing it to 
induce the phosphorylation of MAP2 kinases that phosphorylate and activate downstream 
targets such as JNK. It has been demonstrated that mice deficient in ASK1 were 
significantly protected against APAP hepatotoxicity (Nakagawa et al., 2008). Our data 
show that pharmacological inhibition of ASK1 with a potent and highly selective small 
molecule ASK1 inhibitor can attenuate APAP-induced liver injury as indicated by 
reduced JNK activation, lower oxidant stress and ALT release and limited centrilobular 
necrosis. 
The importance of JNK activation and p-JNK translocation to the mitochondria as a 




(Hanawa et al., 2008 and Saito et al., 2010a) and also recently in primary human 
hepatocytes (Xie et al., 2014). The fact that the ASK1 inhibitor attenuated JNK activation 
in the cytosol, largely prevented the translocation of p-JNK to the mitochondria and 
reduced the mitochondrial oxidant stress was consistent with an effect upstream of JNK 
activation. Several other kinases including mixed-lineage kinase 3 (MLK3) (Sharma et al., 
2012) and glycogen synthase kinase 3β (GSK3β) (Shinohara et al., 2010) were shown to 
be involved in JNK activation during APAP-induced liver injury. Although MLK3 can 
also be activated by oxidant stress, MLK3 is responsible for GSK3β and JNK activation 
(Sharma et al., 2012). In contrast, ASK1 is considered to be mainly involved in the 
prolonged late JNK activation (> 4 h post-APAP administration) (Nakagawa et al., 2008). 
The importance of the prolonged JNK activation for APAP-induced liver injury is 
supported by studies in JNK-deficient mice (Gunawan et al., 2006 and Henderson et al., 
2007), other studies demonstrating that liver injury is decreased when oxidative stress 
and sustained JNK activation are decreased; for example in female mice (Du et al., 2014), 
in Fas receptor-deficient lpr mice ( Williams et al., 2013), or in mice treated with 
allopurinol (Williams et al., 2014). In addition, the increased liver injury after APAP 
overdose in animals deficient in phosphatases, which are known to counteract JNK 
phosphorylation, further supports the critical role of the ASK1-induced JNK activation 
cascade at least in the mouse ( Mobasher et al., 2013 and Wancket et al., 2012). 
The role of ASK1 and JNK activation during APAP overdose in humans remains unclear. 
More recent translational studies support the hypothesis that protein adduct formation and 
mitochondrial dysfunction are important for the human pathophysiology (Davern et al., 




JNK activation and mitochondrial p-JNK translocation in primary human hepatocytes, 
the protection by inhibition of JNK was modest (Xie et al., 2014). In contrast, APAP did 
not induce JNK activation in the metabolically competent human hepatoma cell line 
HepaRG (Xie et al., 2014), which is, however, still susceptible to APAP-induced cell 
injury involving oxidant stress and mitochondrial dysfunction (McGill et al., 2011). Thus, 
whereas the relevance of ASK1 and JNK activation is well documented in the murine 
system, the importance of ASK1 in the human pathophysiology of APAP-induced liver 
injury remains to be further investigated. 
The therapeutic window of pharmacological ASK1 inhibition in APAP 
hepatotoxicity 
In addition to the efficacy of pretreatment with the ASK1 inhibitor, our study also 
demonstrated that administration of the ASK1 inhibitor during a narrow therapeutic 
window after APAP overdose can still be effective. However, the ASK1 inhibitor was not 
more effective than NAC treatment, the standard of care in patients. In addition, the 
combined treatment of NAC and ASK1 inhibitor did not show a relevant additive effect. 
These results indicate that both interventions target the same mechanism in the 
pathophysiology. The faster recovery of hepatic GSH levels mediated by treatment of 
NAC after the metabolism phase leads to enhanced scavenging of reactive oxygen and 
peroxynitrite (Knight et al., 2002, James et al., 2003 and Saito et al., 2010b). Inhibition of 
ASK1 reduces JNK activation, which is critical for the amplification of the mitochondrial 
oxidant stress (Hanawa et al., 2008 and Saito et al., 2010a). Thus, both interventions 
attenuate the mitochondrial oxidant stress, which is responsible for the MPT pore 




The limited therapeutic window of ASK1 inhibition in mice may be related to the rapid 
JNK activation and subsequent translocation to the mitochondria. The ASK1 inhibitor 
was effective only when it was administered before significant p-JNK had translocated to 
the mitochondria, suggesting the primary mechanism of action of the ASK1 inhibitor was 
to prevent JNK activation and translocation. After p-JNK has translocated to the 
mitochondria, the amplification of the oxidant stress may involve other kinases in a feed-
forward mechanism, which no longer depends on ASK1 alone or may involve JNK-
independent mechanisms (Saberi et al., 2014). In either case, these data are not consistent 
with the original hypothesis that ASK1 is only responsible for the late JNK activation. 
Our data suggest that ASK1 inhibition is required relatively early (< 1.5 h after APAP) in 
order to be effective. 
The limited therapeutic window for ASK1 inhibition in mice may not translate to the 
human pathophysiology, which is generally delayed compared to mice with peak injury 
at 36–48 h in humans and around 12 h in mice. The reason for the delay in human 
hepatocytes appears to be related to delay in mitochondrial adduct formation, JNK 
activation and p-JNK translocation to the mitochondria after APAP overdose (Xie et al., 
2014). As a consequence, NAC treatment is still 100% protective even if initiated 6 h 
after APAP and still partially effective when given 15 h after APAP exposure (Xie et al., 
2014). In addition, a JNK inhibitor was still effective when administered 3 h after APAP 
in human hepatocytes (Xie et al., 2014). Thus, the therapeutic window for the ASK1 
inhibitor needs to be assessed in humans but it can be expected to be substantially larger 
than in mice. 




Although JNK activation has been associated with mechanisms of liver injury in many 
disease models including APAP hepatotoxicity (Czaja, 2003 and Gunawan et al., 2006), 
JNK can phosphorylate c-jun and activate the transcription factor AP-1, which can 
promote regeneration by Cyclin D1 gene expression (Schwabe et al., 2003). Because 
regeneration is critical for recovery and survival after APAP-induced liver injury (Apte et 
al., 2009, Bajt et al., 2003 and Bhushan et al., 2013), and because other kinases can 
activate JNK independently of ASK1, it was important to evaluate if the ASK1 inhibitor 
affects regeneration as assessed by the expression of PCNA in the recovering liver. 
Similar to previous interventions such as GSH or NAC (Bajt et al., 2003), which reduced 
APAP-induced liver injury, the ASK1 inhibitor actually enhanced PCNA expression. 
However, using a second ASK1 inhibitor with high oral availability in the diet starting 6 
h after APAP had no effect of PCNA expression during the recovery phase at 48 h. Thus, 
our data demonstrated that 2 different ASK1 inhibitors protected against APAP 
hepatotoxicity and did not inhibit regeneration. Second, the inhibitor GS-444217, which 
has better oral availability than GS-459679, allowed continuous inhibition of ASK1 for 
several days. The fact that no effect on regeneration was observed supports the 
hypothesis that this inhibitor could be used therapeutically. Together, these findings 
indicate that inhibition of ASK1-mediated JNK activation can attenuate liver injury but 
does not affect cell cycle activation and regeneration after APAP-induced liver injury. 
In summary, our data demonstrate that the specific and selective ASK1 inhibitor GS-
459679 protected against APAP-induced liver injury by inhibiting JNK activation, p-JNK 
translocation to the mitochondria and oxidant stress. The inhibitor was effective in this 




administered after APAP. In addition, the ASK1 inhibitor did not inhibit regeneration 
after APAP-induced liver injury. Because of the delayed JNK activation and delayed cell 
injury process in humans, small molecule ASK1 inhibitors may be suitable as therapeutic 












7.1 Discussion- testing interventions on APAP-induced hepatotoxicity 
 
Exploring superior therapeutic options is central in APAP toxicity studies, and research 
on protective interventions has boomed in recent years. Overall, targeting every single 
step of the injury process holds promise for a potential therapy of APAP-induced liver 
injury. However, several concerns need to be addressed during the mechanistic testing. 
First, are we targeting relevant cellular events? The failed attempts on caspase inhibitors 
serve as a good example, as apoptosis does not play a crucial role in the pathogenesis of 
APAP toxicity (Lawson et al., 1999; Williams et al., 2010). Similarly, interventions on 
sterile inflammation pathways are also unable to provide satisfactory results (Jaeschke et 
al., 2012).  
Second, are there any pharmacological molecules available to abrogate the contributing 
event? Genetic models such as gene knockout mice could provide valuable mechanistic 
insights; however, it is the functional and specific small molecule inhibitors, which may 
translate findings in animals to humans.  
Third, are those interventions practically useful? For examples, inhibiting APAP 
metabolism seems the perfect strategy to prevent the hepatotoxicity as it solves the root 
of the problem. However, drug metabolism happens within the first few hours after drug 
ingestion while the overdose patients usually seek for medical attention when symptoms 
of toxicity developed, i.e. mainly after drug metabolism. With that, blocking APAP 




Figure 7.1 A mechanistic evaluation algorithm for potential interventions on APAP 
hepatotoxicity 
  
• Are we targeting relevant cellular events? 
•     Irrevevant events -inhibit apoptosis, block sterile inflammation early on... 
•     Relevant events- reducing JNK activation, improve mitochondrial functions... 
• Are there any interventions available? 
•     Chemical inhibitors/inducers, siRNA, antibodies... 
• Is the intervention practically useful? How is the safety in 
humans? 
•     Unuseful intervention- inhibiting APAP metabolism or protein adduct 
formation... 
• How is the internvention compared with NAC? 





Last but not least, how is the intervention compared with NAC? No matter what the 
protective mechanisms of the potential therapies are, it will be compared to the standard 
of care -NAC treatment. For any potential therapeutic option, a superior efficacy and less 
toxicity than NAC would argue for its market approval by FDA. However, unlike cancer 
treatments, APAP toxicity does not affect as many patients and the costs of developing a 
new drug are prohibitive. Therefore, the best chance of introducing a new therapeutic 
intervention against APAP toxicity would be to repurpose an existing drug approved for 
human use. With that, comparisons with existing treatment are absolutely critical. 
Although molecules like ASKi and JNKi meet all qualifications mentioned above and 
could alleviate APAP-induced liver injury in vivo, however, the inferior efficacies 
compared with NAC pose an obstacle for their translation to clinical trials and market 
approval (Xie et al., 2014; Xie et al., 2015c). Future efforts are warranted for exploration 
of treatment options which requires legitimate mechanistic studies of APAP 
hepatotoxicity.  
As summarized in Table 7.1, an evaluation algorithm could be applied when new 
interventions are tested in the APAP hepatotoxicity model. Among the extensive studies 










7.2 Future directions 
 
APAP overdose patients represent the largest group of both acute liver failure and drug-
induced liver injury. Therefore, further understanding of the mechanistic events is not 
only critical for clinical diagnosis and treatment, but may also reveal novel therapeutic 
intervention strategies that could be targeted by drugs. A few directions worth exploring 
in the future are discussed here. 
First, further investigations are required on the cellular signaling pathways contributing to 
the pathogenesis after APAP. Although a basic signaling network has been established, 
however, knowledge gaps still exist (see above in Chapter 1“Introduction”). In retrospect, 
the exploration of contributing signaling pathways after APAP is not a random shot, and 
several hints have led to the identification of potential targets. Among those hints, one is 
the extrapolation from classical cell death/survival models like TNF-α mediated signal 
transductions to the APAP model. This extrapolation has led to the research on JNK and 
subsequently a series of upstream and downstream mediators including ASK1, MLK3, 
GSK3β, Sab, RIP1, and RIP3. Another lead is mitochondrial dysfunction. The 
mitochondrion is the most critical target among all organelles in APAP, and it controls 
cellular activities including energy supply, cell death, ROS formation, Ca
2+
 homeostasis, 
while it also undergoes mitochondrial dynamics including mitochondrial fission, fusion 
and removal by processes like mitophagy. All these events are closely related to liver 
pathogenesis after APAP and other liver diseases. Future efforts could continue to be 
devoted to mitochondrial biogenesis and programmed necrosis pathways which 




pathways and mediators will be revealed in the future, which will facilitate the 
identification of new potential therapeutic targets.  
Second, improvement of study models is warranted. As there is no perfect model but only 
useful models, all the current in vivo or in vitro systems for studying APAP 
hepatotoxicity bear certain advantages and disadvantages as summarized in Table 7.2.1. 
However, approaches to improve existing models are ongoing. For example, primary 
human hepatocytes (PHH) are the most preferred in vitro model to test drug toxicity; 
however, two major obstacles prevent the widespread usage of PHH, which are limited 
availability and cell dedifferentiation over time. To overcome the former, cryopreserved 
PHH were introduced which allows better and more controlled access to PHH when 
needed. For the latter, more advanced PHH culture systems like 3D culture or sandwich 
culture systems are adapted. Although problems exist as to the improved systems, more 
relevant models could reveal different aspects of the injury mechanisms.  
Third, the search for mechanism-based biomarkers needs to be continued. The 
importance of biomarkers is generally acknowledged for both clinical applications and 
drug development. Traditional clinical endpoints for liver dysfunction are unspecific and 
are unable to predict patient outcomes. Previous efforts have led to the discovery of a 
battery of biomarkers, including HMGB1 (Antonie et al., 2009& 2012), keratin-18 
(Antonie et al., 2009& 2012), micro RNAs (Ward et al., 2014; Vliegenthart et al., 2015), 
APAP-protein adduct (Daven et al., 2006; McGill et al., 2013), mtDNA, nuclear DNA 
(McGill et al., 2012a &2014c), glutamate dehydrogenase (GDH) (McGill et al., 2012a), 
argininosuccinate synthetase (McGill et al., 2014a), acylcarnitines (McGill et al., 2014b), 




disadvantages exist, including the still undefined mechanisms in humans, lack of 
prognostic information or limited improvement over currently used clinical panels, all of 
which largely restrict their clinical utility. Therefore, the translational applicability of 
theses existing biomarkers require further testing. Additional explorations of biomarkers 
based on thorough understanding of injury mechanisms are undoubtedly beneficial for 
either clinical applications or drug development. 
Fourth and as mentioned above in 7.1, the pursuit of novel therapeutic options for APAP 
are critical, which requires better understanding of the injury process from every aspect. 
As discussed in detail in 1.4, current treatment strategies include enhance antioxidant 
defense, targeting signaling pathways, promoting liver regeneration, enhancing 
autophagy, blocking mitochondria MPT and so on. However, none of them have 
managed to outperform the standard antidote NAC. Given that NAC is most effective if 
given early on after APAP ingestion, further investigations of the late injury mechanisms 
and liver regeneration are indispensable for providing new therapeutic targets and better 
treatment options. 
Other future directions include the exploration of macromolecules adducted by NAPQI, 
as no specific proteins have been found to be fully responsible for the injury.  
The importance of APAP-induced hepatotoxicity has gone beyond the toxicity of a single 
OTC, as it also constitutes the most prevalent type of ALF clinically in the US, a classic 
reference model of DILI for industrial drug development, and a human-relevant system to 




With that, every step towards a better understating of the pathogenesis after APAP is 
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